

526 Rec'd PCT/PTO 30 JAN 2001

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 12-99)		ATTORNEY'S DOCKET NUMBER A2996A US U.S. APPLICATION NO. (If known, S. 37 CFR 1.5) 09/744788
<p align="center">TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</p>		
INTERNATIONAL APPLICATION NO. PCT/US99/17116	INTERNATIONAL FILING DATE 28 July 1999 (28. 07. 99)	PRIORITY DATE CLAIMED 30 July 1998 (28. 07. 98) <i>30</i>
TITLE OF INVENTION ISOFORMS OF HUMAN CALCIUM SENSING RECEPTOR		
APPLICANT(S) FOR DO/EO/US Kin T. YU, Richard F. LABAUDINIERE, Larry W. THROWER		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), and Power of Attorney. (unexecuted) <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern other document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: Print EFS, Sequencing Statement, Sequencing diskette, postcard 		
CERTIFICATION UNDER 37 CFR 1.10		
"Express Mail" Mailing Number <u>EL68515429845</u> I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. EO/US <u>Debra L. Wetherill</u> (Type or print name of person mailing paper)		Date of Deposit <u>30 January 2001</u> <u>Debra L. Wetherill</u> (Signature of person mailing paper)

JCO2 Rec'd PCT/PTO 3 0 JAN 2001

U.S. APPLICATION NO. (If Known, see CFR 1.7)		INTERNATIONAL APPLICATION NO. PCT/FR99/01813		ATTORNEY'S DOCKET NUMBER ST98023A			
<div style="float: left; width: 30%; font-size: 2em; font-weight: bold;">09/744788</div> <div style="clear: both;"></div>							
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445 (a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$ 96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS		PTO use only	
				\$840.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
Claims		Number Filed	Number Extra	Rate			
Total Claims	50 - 20 =	30	X \$	18.00	\$ 540.00		
Independent Claims	6 - 3 =	3	X \$	80.00	\$ 240.00		
Multiple dependent claim(s) (if applicable)			+ \$270.00		\$		
TOTAL OF ABOVE CALCULATIONS =				\$ 780.00			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$			
SUBTOTAL =				\$			
Processing fee of \$130.00 for furnishing the English translation later the [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$		
TOTAL NATIONAL FEE =				\$			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$			
TOTAL FEES ENCLOSED =				\$			
				Amount to be refunded	\$		
				charged	\$1,620.00		
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fee is enclosed.							
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>18-1982</u> in the amount of <u>\$1,620.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>18-1982</u> . A duplicate copy of this sheet is enclosed.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO:							
Customer No. 005487				Signature <i>Karen I Krupen</i>			
				Name Karen I. Krupen			
				Registration Number #34,647			
				Date <i>30 January 2001</i>			

Isoforms of Human Calcium Sensing Receptor

FIELD OF THE INVENTION

The present invention relates to isoforms of a human calcium sensing receptor, and to the genes encoding these isoforms. The invention further relates to methods of screening for agonists or antagonists of the isoforms, particularly with respect to calcium receptor activity, to diagnostic uses of these isoforms and to therapeutic uses of the agonists or antagonists. The invention also relates to gene therapy using the genes encoding the receptor isoforms or molecules capable of down-regulating receptor activity, such as antisense sequences.

BACKGROUND OF THE INVENTION

Calcium is an extracellular messenger (Brown et al. (1995) Cell 83:679-682). Serum calcium levels are regulated by 1,25-dihydroxyvitamin D₃, parathyroid hormone, and calcitonin. A calcium sensing receptor (CaSR) has been identified in bovine parathyroid (WO 94/18959; Brown et al. (1993) Nature 366: 575-580). Cloning of the cDNA encoding this receptor (CaSRa) revealed a G-protein-coupled receptor featuring a large extracellular domain, coupled to a seven membrane spanning domain similar to those found in members of the G protein coupled receptor superfamily. This receptor has been shown to play a key role in Ca⁺⁺ homeostasis through regulation of parathyroid hormone secretion and renal tubular calcium reabsorption. This receptor recognizes calcium and other polyvalent cations and is coupled by changes in phosphoinositide turnover to the release of calcium from intracellular stores. In addition to its abundant expression in parathyroid gland and kidney, full length CaSRa transcripts have also been found in brain, thyroid, intestine, bone marrow and keratinocytes. The complete cDNA sequence encoding the corresponding human form of CaSRa has recently been reported (Freichel et al. (1996) Endocrinology 137:3842-3848). This 3234 base pair nucleotide sequence (SEQ ID NO: 11) encodes a protein having 1078 amino acids (SEQ ID NO: 12). Various forms of the CaSR, particularly from bone marrow cells, are also disclosed by House et al. ((1997) J. Bone Min. Res. 12:1959-1970) and in US patents 5,688,938 and 5,763,569. The presence of calcium receptors in bone, suggests that they are involved in bone remodeling (Quarles (1997) J. Bone Min. Res. 12, 1971-1974).

An alternatively spliced form of CaSRa, has been identified in human medullary thyroid carcinoma and keratinocytes (see Freichel et al. *supra*). The medullary thyroid carcinoma isoform, designated CaSRb, contains a 307 base pair deletion between nucleotides 186 and 495, corresponding to exon 2. This deletion results in a reading frame shift and premature termination at nucleotide 766. Translation of CaSRb transcript could yield an extracellular portion of the receptor without the 7 transmembrane anchor and cytosolic tail. Therefore, CaSRb may be a secretory protein, and, although its

exact function has yet to be determined, by analogy to other known soluble receptors it may play a role in modulating the interaction of native CaSR with its cationic ligands.

A second isoform of CaSRa has also been identified in keratinocytes (Oda et al. (1997) FASEB J. 11(9): A925; Abstract #395). This form (CaSRc) lacks exon 4, encoding a portion of the extracellular domain of the receptor including a region of acidic amino acids which may mediate calcium binding, and is present in differentiated cells.

However, there is a need in the art to better understand calcium homeostasis. In particular, there is a need in the art to better understand calcium regulation through the CaSR. Isoforms of the wild-type CaSR could be expected to exhibit different pharmacological profiles and signaling properties relative to the wild-type. For example, different isoforms could couple differentially or uniquely to known or unknown signalling pathways, including phosphoinositide turnover, calcium mobilization, protein kinase C activation, cAMP production, and other ion channel activity. Alternatively, variant isoforms may exhibit different cell surface expression, metabolic half-life, or intracellular trafficking, when compared to the wild-type, or behave in a dominant negative or positive fashion, thereby over-riding the functionality of the wild-type receptor expressed in the same tissue.

The present invention addresses the need in the art, as discussed below. Specifically, Applicants present evidence that CaSRb is also found in human kidney. Significantly, Applicants have also identified in human kidney two other alternatively spliced CaSR transcripts (CaSRc and d) with deletions from nucleotides 1378-1608 and 1075 to 1386, respectively.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

SUMMARY OF THE INVENTION

As noted above, the present invention concerns identification of isoforms of a human calcium sensing receptor (CaSR). The present invention reveals the presence of multiple alternatively spliced transcripts of CaSR in human kidney. Two such isoforms identified, CaSRc and d arise from partial deletion of the wild type sequence. The nucleotide deletions in CaSRc and d have no effect on the reading frame. Thus, CaSRc and d will yield receptor proteins with about 90-100 amino acid stretches deleted from the extracellular domain. These deletions cover a respective extracellular sequence rich in acidic residues (approximately 4%). The location and the charge characteristics of the deleted sequences in CaSRc and d suggest that these two CaSR splice variants may exhibit different cation sensing property from the wild type receptor.

Thus, in a first aspect, the present invention provides isolated nucleic acids encoding an isoform of a human calcium sensing receptor, wherein the nucleic acid comprises about 2922 to about 3003

nucleotides and has a deletion of at least about 231 nucleotides when compared to the wild-type form of the receptor as depicted in SEQ ID NO:11. The term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. Preferably, the deletion is in the region encoding the extracellular domain of the receptor.

5 In a preferred embodiment of the invention, the deletion is from about nucleotides 1075-1386 of SEQ ID NO:11. In another preferred embodiment, the deletion is from about nucleotides 1378-1608 of SEQ ID NO:11. Alternatively, the deletion is from about nucleotides 1075-1608 of SEQ ID NO:11.

In another embodiment, the isolated nucleic acid of the present invention has at least one property selected from:

10 it can be amplified by polymerase chain reaction (PCR) using an oligonucleotide primer derived from SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11;

it hybridizes under stringent conditions with a nucleic acid having a nucleotide sequence as depicted in SEQ ID NO:7 or SEQ ID NO:9; and

it encodes a polypeptide having an amino acid sequence selected from the group consisting of
15 SEQ ID NO:8, SEQ ID NO:10, and allelic variants thereof.

Preferably, the nucleic acid the invention can be amplified with at least one oligonucleotide primer selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:6.

In still another preferred embodiment of the invention, the isolated nucleic acid encodes a CaSR isoform comprising an amino acid sequence as depicted in SEQ ID NO:8 (CaSRc) or SEQ ID NO:10
20 (CaSRd), or allelic variants thereof. Preferably, the isolated nucleic acid comprises a nucleotide sequence as depicted in SEQ ID NO:7 or SEQ ID NO:9, or allelic variants thereof.

As can be readily appreciated by one of ordinary skill in the art, one effective way to prepare a nucleic acid of the invention, particularly a cDNA, is to amplify the nucleic acid from a cDNA library comprising a coding sequence for a CasR isoform using PCR. Various PCR primers, corresponding to
25 any desired segment from SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11 can be used in accordance with the invention. In specific embodiments, *infra*, PCR primers having the sequences depicted in SEQ ID NOS: 1-6 were used to amplify and isolate nucleic acids of the invention. Alternatively, a nucleic acid of the invention can be isolated or identified with an oligonucleotide probe, *e.g.*, of at least 10 bases, which hybridizes under stringent conditions to a nucleotide having the sequence or the complementary
30 sequence depicted in SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11. In a specific aspect, the oligonucleotide can be used in a method for detecting genomic DNA (Southern analysis) or expression of mRNA (Northern analysis) encoding a CaSR isoform in a cell. In either case, the method comprises contacting a sample from the cell with the oligonucleotide which is detectable, *e.g.*, by labeling with a radioisotope or a chromophore or fluorophore, and detecting hybridization of the oligonucleotide with
35 genomic DNA or mRNA in the sample, wherein detection of hybridization of the oligonucleotide with

genomic DNA indicates the presence of a gene encoding a CaSR isoform in the genome, and detection of hybridization with mRNA indicates expression of mRNA encoding a CaSR isoform. It is also possible to use quantitative methods, *e.g.*, to detect the number of *CaSR* genes in the genome, or to detect an increase or decrease in the level of expression of mRNA.

5 An oligonucleotide of the invention can also be an antisense oligonucleotide, *i.e.*, one that binds to mRNA encoding a CaSR isoform and prevents its translation in the cell. Such an antisense molecule can be encoded by a vector expressed in the cell, or can be a synthetic oligonucleotide, preferably one that includes non-phosphoester bonds so that it is resistant to intracellular nucleases.

10 In another aspect, the invention provides a vector comprising nucleic acids encoding an isoform of a human calcium sensing receptor. Preferably, the nucleic acid is operatively associated with an expression control sequence permitting expression of the receptor in an expression competent host cell. The vector may be an RNA molecule, a plasmid DNA molecule, or a viral vector. The viral vector may be a retrovirus, adenovirus, adeno-associated virus, herpes virus, or vaccinia virus.

15 In still another aspect, the invention is directed to host cells transfected with a vector comprising nucleic acids encoding an isoform of a human calcium sensing receptor. The host cell may be a bacterial cell, a yeast cell, or a mammalian cell. The host cells of the invention can be used to produce a CaSR isoform recombinantly. This method comprises culturing the host cell in culture medium under conditions permitting expression of the isoform. Therefore, another aspect of this invention is a method for expressing an isoform of human calcium sensing receptor comprising:

20 culturing the host cell in culture medium under conditions permitting expression of the recombinant receptor; and
identifying cells expressing the receptor on their surface.

25 The invention also provides an isolated isoform of a human calcium sensing receptor, wherein the isoform comprises about 974 to about 1001 amino acids and has a deletion of at least about 77 amino acids when compared to the wild-type form of the receptor as depicted in SEQ ID NO:12. The deletion may be from the extracellular domain of the receptor, such as from about amino acids 358-462, about amino acids 460-536 or about amino acids 358-536 of SEQ ID NO:12. In particular, a CaSR isoform of the invention comprises an amino acid sequence as depicted in SEQ ID NO:8 or SEQ ID NO:10, or allelic variants thereof.

30 The present invention advantageously provides methods of screening for molecules that modulate the activity of CaSR isoforms, and thus calcium levels. In particular, the invention provides a method of screening for agonists or antagonists of a CaSR isoform activity, the method comprising incubating a test sample with a CaSR isoform, measuring CaSR isoform activity and comparing the

activity to that in the absence of the test sample. Any of the screening methods in the art can be used, particularly high throughput screening. In a specific embodiment, the method comprises screening compounds for their ability to influence intracellular calcium concentration. The compounds may be tested alone, in conjunction with an elevation in extracellular calcium concentration, or in the presence of other agonists or antagonists of CaSR isoform activity. Intracellular calcium can be measured with a fluorescent indicator, such as fura-2. Screening methods of the invention permit the identification of CaSR agonists (calcimimetics) or antagonists (calcilytics).

In yet a further embodiment, the present invention provides pharmaceutical compositions and methods for the treatment of a patient suffering from a disease or disorder associated with abnormal calcium levels, such as in the plasma, by the administration of a therapeutically effective amount of a compound capable of modulating the activity of a CaSR isoform. The compound may be specific for a CaSR isoform. Such diseases include, for example, hyperparathyroidism (primary and secondary) and osteoporosis. Other diseases include Paget's disease, hypercalcemia malignancy, and hypertension. The compound may be a calcimimetic or calcilytic identified using the screening assays of the invention. Alternatively, the disease or disorder is treated using gene therapy.

In one embodiment, the cells of a patient have been transfected with a vector encoding a CaSR isoform under conditions permitting expression of the isoform.

Alternatively, where desired, the invention provides a method of inhibiting CaSR activity in a patient's cell comprising decreasing the level of CaSR in the cell. The level of CaSR protein can be decreased by introducing a CaSR antisense nucleic acid into the cell, which antisense nucleic acid hybridizes under intracellular conditions to a CaSR mRNA. Alternatively, the level of CaSR protein can be decreased by introducing a single chain Fv antibody (scFv) that specifically binds a CaSR isoform, or nucleic acid encoding and intracellular antibody against the isoform, into the cell at a level sufficient to bind to and inactivate the CaSR.

Yet another object of the invention is to provide for high level expression of CaSR isoforms, either by fermentation of transfected or transduced cells to recover purified protein, or *in vivo* in cells for further testing *in vitro* or for regulation of calcium homeostasis *in vivo*, *e.g.*, for gene therapy.

A particular object of the invention is to provide for screening of small molecule modulators, *e.g.*, agonists and antagonists, of CaSR activity, particularly of specific CaSR isoforms.

These and other objects are addressed by this invention, which is explained in greater detail in the attached drawings and the following Detailed Description and Examples.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1. Diagram of the structures of the wild-type calcium sensing receptor (CaSRa), splice variant

CaSRd (lacking amino acids encoded by nucleotides 1075-1386), and splice variant CaSRc (lacking amino acids encoded by nucleotides 1378-1608).

DETAILED DESCRIPTION OF THE INVENTION

5 This invention is based, in part, on the identification of isoforms of a human calcium sensing receptor, termed herein CaSR.

The invention accordingly relates to nucleic acids encoding CaSR isoforms, to the purified protein, to cells which express nucleic acids encoding isoforms of CaSR, in particular splicing variants, and to their use in screening for small molecules or natural products, which agonize or antagonize the
10 activity of the CaSR.

The invention can also be used for the treatment of diseases or disorders associated with an abnormal level of calcium, including gene therapy applications (both coding and antisense molecules can be of use).

In addition, anti-CaSR antibodies can be used in diagnostic and purification applications.

15 These and other aspects of the invention, particularly isolation of CaSR genes, expression of CaSR protein, generation of anti-CaSR antibodies, screening assays for agonists or antagonists of CaSR activity and delivery of CaSR encoding vectors, in particular for gene therapy applications, are discussed in detail in the following sections. Section headers are provided merely for the reader's convenience, and are not to be deemed limiting in any respect.

Genes Encoding Calcium Sensor Receptor Isoforms

The present invention contemplates isolation of genes encoding isoforms of a human calcium sensing receptor. As used herein, the term "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes cDNA and genomic DNA nucleic acids.

25 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II
30 (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "cloning vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, *i.e.*, capable of replication under its own control. Cloning vectors may be capable of replication in one cell type, and expression in another ("shuttle vector").

A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. The transforming DNA can be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (*see* Sambrook et al., *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a T_m of 55°, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher T_m , *e.g.*, 40% formamide, with 5x or 6x SCC. High stringency hybridization

conditions correspond to the highest T_m , e.g., 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., *supra*, 9.50-0.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.

In a specific embodiment, the term "standard hybridization conditions" refers to a T_m of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the T_m is 60°C; in a more preferred embodiment, the T_m is 65°C.

As used herein, the term "oligonucleotide" refers to a nucleic acid, generally of at least 18 nucleotides, that is specifically hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding CaSR, or an isoform thereof. Oligonucleotides can be labeled, e.g., with ^{32}P -nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid encoding a CaSR, or an isoform thereof. In another embodiment, oligonucleotides (one or both of which may be labeled) can be used as PCR primers, either for cloning CaSR isoforms, or to detect the presence of nucleic acids encoding CaSR isoforms. In a further embodiment, an oligonucleotide of the invention can form a triple helix with a CaSR DNA molecule. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription

termination sequence will usually be located 3' to the coding sequence. In this case, the nucleic acid is "operatively associated" with an expression control sequence permitting expression of the protein in an expression competent host cell

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced (if the coding sequence contains introns) and translated into the protein encoded by the coding sequence.

As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (*e.g.*, the immunoglobulin superfamily) and homologous proteins from different species (*e.g.*, myosin light chain, etc.) (Reeck et al., 1987, Cell 50:667). Such proteins (and their encoding genes) have sequence homology, as reflected by their high degree of sequence similarity.

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (*see* Reeck et al., *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and not a common evolutionary origin.

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, *e.g.*, Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid

Hybridization, *supra*.

Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 30% of the amino acids are identical, or greater than about 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, *Version 7*, Madison, Wisconsin) pileup program.

The term "corresponding to" is used herein to refer similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. A nucleic acid or amino acid sequence alignment may include spaces. Thus, the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.

A gene encoding a CaSR isoform, whether genomic DNA or cDNA, can be isolated from a human cDNA or genomic library. Methods for obtaining genes encoding CaSR isoforms are well known in the art, as described above (*see, e.g.,* Sambrook et al., 1989, *supra*).

Accordingly, any human cell potentially can serve as the nucleic acid source for the molecular cloning of a CaSR isoform gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.,* a DNA "library"), and preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein (*e.g.,* brain, thyroid and kidney cDNA), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (*See, for example, Sambrook et al., 1989, supra; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II*). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. In specific embodiments, isoforms CaSRc and CaSRd were isolated from a human kidney cell library. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

Once the DNA fragments are generated, identification of the specific DNA fragment containing gene encoding a CaSR isoform may be accomplished in a number of ways. For example, DNA fragments may be screened by nucleic acid hybridization to a labeled probe (Benton and Davis, 1977, *Science* 196:180; Grunstein and Hogness, 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In a specific embodiment, Northern hybridization conditions are used to identify mRNA splicing variants of a CaSR gene.

Further selection can be carried out on the basis of the properties of the gene, *e.g.,* if the gene encodes a protein product having the isoelectric, electrophoretic, amino acid composition, or partial

amino acid sequence of a CaSR isoform as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, *e.g.*, has similar or identical electrophoretic migration, isoelectric focusing or non-equilibrium pH gel electrophoresis behavior, proteolytic digestion maps, or antigenic properties as known for CaSR. In a specific embodiment, the isoform is recognized by a polyclonal antibody that does not recognize wild-type CaSR.

The present invention relates to genes (*e.g.*, cDNAs) encoding allelic variants, splicing variants, analogs, and derivatives of CaSR isoforms of the invention that have the same or homologous functional activity as the isoforms. The production and use of derivatives and analogs related to CaSR isoforms are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with an isoform of the invention. In particular, such an analog can bind calcium. Alternatively, an allelic variant can comprise a mutation that results an inability to bind calcium.

Derivatives can be made by altering encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity relative to native CaSR isoforms.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a gene encoding a CaSR isoform, including an amino acid sequence that contains a single amino acid variant, may be used in the practice of the present invention. These include but are not limited to allelic genes, homologous genes from other species, and nucleotide sequences comprising all or portions of CaSR isoform genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, the derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a CaSR isoform including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine

and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

Particularly preferred substitutions are:

- 5 - Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free CONH₂ can be maintained.

10 Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic" site (*i.e.*, His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces b-turns in the protein's structure.

15 The genes encoding CaSR isoforms, derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding an CaSR isoform, derivative or analog, care
20 should be taken to ensure that the modified gene remains within the same translational reading frame as the CaSR gene (SEQ ID NO:11), uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

25 Additionally, the CaSR isoform-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Preferably, such mutations enhance the functional activity of the mutated gene product. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem. 253:6551; Zoller and Smith, 1984, DNA 3:479-488; Oliphant et al., 1986, Gene 44:177; Hutchinson et al., 1986, Proc. Natl.
30 Acad. Sci. U.S.A. 83:710), use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not

limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, *E. coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, e.g., pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle vector plasmid, which provides for expansion in a cloning cell, e.g., *E. coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *E. coli* and *Saccharomyces cerevisiae* by linking sequences from an *E. coli* plasmid with sequences from the yeast 2 μ plasmid.

Expression of CaSR Isoforms

The nucleotide sequence coding for CaSR isoforms, or derivatives or analogs thereof, including a chimeric protein, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the nucleic acid encoding a CaSR isoform of the invention is operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences. An expression vector also preferably includes a replication origin.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding a CaSR, a CaSR isoform and/or its flanking regions.

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

A recombinant CaSR isoform of the invention, derivative, or analog thereof, may be expressed chromosomally, after integration of the coding sequence by recombination. In this regard, any of a number of amplification systems may be used to achieve high levels of stable gene expression (See Sambrook et al., 1989, *supra*).

5 The cell into which the recombinant vector comprising the nucleic acid encoding a CaSR isoform is cultured in an appropriate cell culture medium under conditions that provide for expression of protein by the cell.

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

Expression of a gene may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the b-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the *tac* promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987,

Science 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

Expression vectors containing a nucleic acid encoding a CaSR isoform of the invention can be identified by five general approaches: (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, (d) analyses with appropriate restriction endonucleases, and (e) expression of inserted sequences. In the first approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted marker gene. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (*e.g.*, b-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In another example, if the nucleic acid encoding a CaSR isoform is inserted within the "selection marker" gene sequence of the vector, recombinants containing the nucleic acid insert can be identified by the absence of the gene function. In the fourth approach, recombinant expression vectors are identified by digestion with appropriate restriction enzymes. In the fifth approach, recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant, provided that the expressed protein assumes a functionally active conformation.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, *e.g.*, *E. coli* plasmids col El, pCR1, pBR322, pMal-C2, pET, pGEX (Smith *et al.*, 1988, Gene 67:31-40), pMB9 and their derivatives, plasmids such as RP4; phage DNAs, *e.g.*, the numerous derivatives of phage I, *e.g.*, NM989, and other phage DNA, *e.g.*, M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2m plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage

DNA or other expression control sequences; and the like.

For example, in a baculovirus expression systems, both non-fusion transfer vectors, such as but not limited to pVL941 (*Bam*H1 cloning site; Summers), pVL1393 (*Bam*H1, *Sma*I, *Xba*I, *Eco*RI, *Not*I, *Xma*III, *Bgl*II, and *Pst*I cloning site; Invitrogen), pVL1392 (*Bgl*II, *Pst*I, *Not*I, *Xma*III, *Eco*RI, *Xba*I, *Sma*I, and *Bam*H1 cloning site; Summers and Invitrogen), and pBlueBacIII (*Bam*H1, *Bgl*II, *Pst*I, *Nco*I, and *Hind*III cloning site, with blue/white recombinant screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (*Bam*H1 and *Kpn*I cloning site, in which the *Bam*H1 recognition site begins with the initiation codon; Summers), pAc701 and pAc702 (same as pAc700, with different reading frames), pAc360 (*Bam*H1 cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen(195)), and pBlueBacHisA, B, C (three different reading frames, with *Bam*H1, *Bgl*II, *Pst*I, *Nco*I, and *Hind*III cloning site, an N-terminal peptide for ProBond purification, and blue/white recombinant screening of plaques; Invitrogen (220)) can be used.

Mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as the dihydrofolate reductase (DHFR) promoter, *e.g.*, any expression vector with a *DHFR* expression vector, or a *DHFR*/methotrexate co-amplification vector, such as pED (*Pst*I, *Sal*I, *Sba*I, *Sma*I, and *Eco*RI cloning site, with the vector expressing both the cloned gene and *DHFR*; see Kaufman, *Current Protocols in Molecular Biology*, 16.12 (1991). Alternatively, a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (*Hind*III, *Xba*I, *Sma*I, *Sba*I, *Eco*RI, and *Bcl*I cloning site, in which the vector expresses glutamine synthase and the cloned gene; Celltech). In another embodiment, a vector that directs episomal expression under control of Epstein Barr Virus (EBV) can be used, such as pREP4 (*Bam*H1, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive Rous Sarcoma Virus Long Terminal Repeat (RSV-LTR) promoter, hygromycin selectable marker; Invitrogen), pCEP4 (*Bam*H1, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive human cytomegalovirus (hCMV) immediate early gene, hygromycin selectable marker; Invitrogen), pMEP4 (*Kpn*I, *Pvu*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, *Bam*H1 cloning site, inducible methallothionein IIa gene promoter, hygromycin selectable marker; Invitrogen), pREP8 (*Bam*H1, *Xho*I, *Not*I, *Hind*III, *Nhe*I, and *Kpn*I cloning site, RSV-LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (*Kpn*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, and *Bam*HI cloning site, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen). Selectable mammalian expression vectors for use in the invention include pRc/CMV (*Hind*III, *Bst*XI, *Not*I, *Sba*I, and *Apa*I cloning site, G418 selection; Invitrogen), pRc/RSV (*Hind*III, *Spe*I, *Bst*XI, *Not*I, *Xba*I cloning site, G418 selection; Invitrogen), and others. Vaccinia virus mammalian expression vectors (*see*, Kaufman, 1991, *supra*) for use according to the invention include but are not

limited to pSC11 (*Sma*I cloning site, TK- and b-gal selection), pMJ601 (*Sal*I, *Sma*I, *Afl*I, *Nar*I, *Bsp*MI, *Bam*HI, *Apa*I, *Nhe*I, *Sac*II, *Kpn*I, and *Hind*III cloning site; TK- and b-gal selection), and pTKgptF1S (*Eco*RI, *Pst*I, *Sal*I, *Acc*I, *Hind*II, *Sba*I, *Bam*HI, and *Hpa*I cloning site, TK or XPRT selection).

Yeast expression systems can also be used according to the invention to express isoforms of a
5 CaSR. For example, the non-fusion pYES2 vector (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Gst*XI, *Eco*RI, *Bst*XI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning sit; Invitrogen) or the fusion pYESHisA, B, C (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Bst*XI, *Eco*RI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning site, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), to mention just two, can be employed according to the invention.

10 Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as
15 baculovirus; yeast vectors; bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing
20 and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. Expression in yeast can produce a biologically active product. Expression in eukaryotic cells can increase the likelihood of "native" folding. Moreover, expression in mammalian cells can provide a tool for reconstituting, or constituting, CaSR activity. Furthermore, different vector/host expression systems may affect processing reactions,
25 such as proteolytic cleavages, to a different extent.

Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*,
30 Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990).

Soluble forms of the protein can be obtained by collecting culture fluid, or solubilizing inclusion bodies, *e.g.*, by treatment with detergent, and if desired sonication or other mechanical processes, as described above. The solubilized or soluble protein can be isolated using various techniques, such as polyacrylamide gel electrophoresis (PAGE), isoelectric focusing, 2-dimensional gel electrophoresis,

chromatography (e.g., ion exchange, affinity, immunoaffinity, and sizing column chromatography), centrifugation, differential solubility, immunoprecipitation, or by any other standard technique for the purification of proteins.

Antibodies to CaSR Isoforms

The invention provides an antibody which specifically binds a CaSR isoform. Such antibodies can be used diagnostically, to detect the presence and optionally the quantity of the isoform in cells. Antibodies of the invention, particularly single chain Fv antibodies (scFv) can also be used therapeutically, to suppress CaSR activity (see below). In a specific embodiment, the antibody recognizes an epitope which is not present in the wild type receptor, CaSRa. In another specific embodiment, exemplified *infra*, the antibody is polyclonal. Monoclonal antibodies, and antibody fragments (in addition to scFv antibodies) are also contemplated by this invention. Using the antibody of the invention, one can specifically detect expression of a CaSR isoform in a cell by contacting a sample from the cell with the antibody under conditions permitting binding of the antibody to the protein in the sample, and detecting binding of the antibody to a protein in the sample, wherein detection of binding of the antibody to the protein indicates expression of a CaSR isoform in the cell. Using quantitative immunoassay or Western blotting methods, it is possible to quantitate the amount of CaSR, and particularly to detect increases or decreases in the amount of CaSR relative to the cell at an earlier time, or to normal cells.

According to the invention, a human CaSR isoform produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an antigen or immunogen to generate antibodies that recognize the polypeptide. A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, *i.e.*, capable of eliciting an immune response without a carrier. Preferably, the antigenic polypeptide comprises an epitope and/or a sequence not present in the wild-type CaSRa, and elicits antibodies which bind to a CaSR isoform.

Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. The antibodies of the invention may be cross reactive, *e.g.*, they may recognize CaSR isoforms from different species. Polyclonal antibodies have greater

likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single isoform of CaSR. In a preferred embodiment, the antibodies are capable of specifically recognizing an isoform of CaSR, and are not capable of recognizing the wild-type CaSR.

Various procedures known in the art may be used for the production of polyclonal antibodies.

5 For the production of antibody, various host animals can be immunized by injection with the CaSR isoform, or a derivative (*e.g.*, fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, a polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species,
10 including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies against the isoform, or fragment, analog, or derivative
15 thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein [*Nature* 256:495-497 (1975)], as well as the trioma technique, the human B-cell hybridoma technique [Kozbor et al., *Immunology Today* 4:72 1983]; Cote et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030 (1983)], and the EBV-hybridoma technique to produce human monoclonal
20 antibodies [Cole et al., in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals [International Patent Publication No. WO 89/12690, published 28 December 1989]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison et al., *J. Bacteriol.* 159:870 (1984); Neuberger et al., *Nature* 312:604-608 (1984); Takeda et al., *Nature*
25 314:452-454 (1985)] by splicing the genes from a mouse antibody molecule specific for a CaSR isoform together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in
30 particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain Fv (scFv) antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce CaSR isoform-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries [Huse et al., *Science*

246:1275-1281 (1989)] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a CaSR isoform.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of a CaSR isoform, one may assay generated hybridomas for a product which binds to an isoform containing such epitope. For selection of an antibody specific to an isoform from a particular species of animal, one can select on the basis of positive binding with a CaSR isoform expressed by or isolated from cells of that species of animal, but which does not bind the wild-type CaSR.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the CaSR isoform, *e.g.*, for Western blotting, imaging the isoform *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art.

In a specific embodiment, antibodies that agonize or antagonize the activity of CaSR, and, in particular, are specific for a CaSR isoform, can be generated. Such antibodies can be tested using the assays described *infra* for identifying ligands. In particular, such antibodies can be scFv antibodies expressed intracellularly.

Screening Assays

Identification and isolation of a gene encoding isoforms of a CaSR of the invention provides for expression of these isoforms in quantities greater than can be isolated from natural sources, or in

indicator cells that are specially engineered to indicate CaSR activity after transfection or transformation of the cells. Accordingly, in addition to rational design of agonists and antagonists based on the structures of CaSR isoforms, the present invention contemplates an alternative method for identifying specific ligands of CaSR isoforms using various screening assays known in the art.

5 Any screening technique known in the art can be used to screen for CaSR agonists or antagonists. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to and agonize (calcimimetics) or antagonize (calcilytics) CaSR activity *in vivo*. For example, natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize CaSR activity. The present invention provides both
10 the means and methodology for identifying compounds capable of modulating CaSR activity, including the specific modulation of CaSR isoforms. Screening assays for calcimimetics and calcilytics are discussed in WO 94/18959 and US Pat. No. 5,763,569, the entire contents of which are incorporated herein by reference.

In a preferred screening assay compounds are assayed for their ability to influence intracellular
15 calcium concentration. The compounds may be tested alone, in conjunction with an elevation in extracellular calcium concentration, or in the presence of other agonists or antagonists of CaSR isoform activity. Agonists include neomycin, di- and tri-valent cations (gadolinium, calcium, magnesium, strontium, barium, lanthanum), polyamines and other known calcimimetics. Intracellular calcium is measured with the fluorescent indicator, fura-2 (from Molecular Probes). For example, HEK-293 cells
20 transfected with a nucleic acid encoding a CaSR isoform is loaded in buffer containing 0.5uM fura-2, 20mM HEPES, pH 7.35, 0.1% BSA, 0.5mM CaCl₂, 0.5mM MgCl₂, 6.7mM KCl, 3mM glucose and 142mM NaCl for 45 min at 37°C. The cells are washed and resuspended to about 2 x 10⁶ cells/ml in the loading buffer without fura-2. For intracellular calcium measurement, cells were placed in a quartz cuvette equilibrated at 37°C. Fluorescence is detected using excitation monochrometers centered at 340
25 and 380 nm and emission light collected at 505 nm.

Knowledge of the primary sequence of CaSR isoforms, and the similarity of their sequences with proteins of known function, can provide an initial clue as the inhibitors or antagonists of the protein. Identification and screening of antagonists is further facilitated by determining structural features of the protein, *e.g.*, using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry,
30 and other techniques for structure determination. These techniques provide for the rational design or identification of agonists and antagonists.

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, et al., *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin et al., *Science*, 249:404-406 (1990)], very large libraries can be constructed

(10^6 - 10^8 chemical entities). A second approach uses primarily chemical methods, of which the Geysen method [Geysen et al., *Molecular Immunology* 23:709-715 (1986); Geysen et al. *J. Immunologic Method* 102:259-274 (1987)] and the method of Fodor et al. [*Science* 251:767-773 (1991)] are examples. Furka et al. [*14th International Congress of Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter et al. [U.S. Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries [Needels et al., *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer et al., *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam et al., International Patent Publication No. WO 92/00252; Kocis et al., International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for CaSR ligands according to the present invention.

The screening can be performed with recombinant cells that express a CaSR isoform, or alternatively, using purified protein, *e.g.*, produced recombinantly, as described above. For example, the ability of a labeled, soluble CaSR isoform that includes the extracellular calcium binding portion of the molecule, can be used to screen libraries, as described in the foregoing references.

In one embodiment, a CaSR isoform may be directly labeled. In another embodiment, a labeled secondary reagent may be used to detect binding of an isoform to a molecule of interest, *e.g.*, a molecule attached to a solid phase support. Binding may be detected by *in situ* formation of a chromophore by an enzyme label. Suitable enzymes include, but are not limited to, alkaline phosphatase and horseradish peroxidase. In a further embodiment, a two color assay, using two chromogenic substrates with two enzyme labels on different acceptor molecules of interest, may be used. Cross-reactive and singly-reactive ligands may be identified with a two-color assay

Other labels for use in the invention include colored latex beads, magnetic beads, fluorescent labels (*e.g.*, fluoresceine isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, especially Eu^{3+} , to name a few fluorophores), chemiluminescent molecules, radio-isotopes, or magnetic resonance imaging labels. Two color assays may be performed with two or more colored latex beads, or fluorophores that emit at different wavelengths. Labeled may be detected visually or by mechanical/optical means. Mechanical/optical means include fluorescence activated sorting, *i.e.*, analogous to FACS, and micromanipulator removal means.

As exemplified herein, the level of the CaSR isoform can be evaluated by metabolic labeling of the proteins. As the metabolic labeling occurs during *in vitro* incubation of the tissue biopsy in the presence of culture medium supplemented with [³⁵S]-methionine, the level of each of the markers detected may be affected by the *in vitro* conditions. In addition to metabolic (or biosynthetic) labeling with [³⁵S]-methionine, the invention further contemplates labeling with [¹⁴C]-amino acids and [³H]-amino acids (with the tritium substituted at non-labile positions). Thus, a sample or library of compounds can be directly analyzed after labeling of the proteins therein, *e.g.*, by colorimetric staining using silver, gold, coomassie blue, or amido-schwartz, to mention a few techniques; isotopic labeling, *e.g.*, with [³²P]-orthophosphate, [¹²⁵I], [¹³¹I]; fluorescent or chemiluminescent tags; and immunological detection with labeled antibody or specific binding partner of a marker.

Pharmaceutical Compositions and Therapy

Diseases or disorders associated with calcium homeostasis, and therefore, the CaSR, are known in the art. Such diseases are related to the functional responses of cells to calcium, such as parathyroid hormone secretion from parathyroid cells, calcitonin secretion by C-cells and bone resorption by osteoclasts. An example is hyperparathyroidism, which results in elevated levels of parathyroid hormone in the plasma. Therefore, a method of decreasing plasma parathyroid hormone levels is a way of treating hyperparathyroidism. Alternatively, increased levels of plasma calcitonin are associated with inhibition of bone resorption. Inhibition of bone resorption offers a way to treat osteoporosis, for example. The present invention provides both the means and methodology for identifying compounds capable of modulating CaSR activity, including the specific modulation of CaSR isoforms, and of using these compounds for the treatment of diseases or disorders associated with abnormal calcium levels.

Therefore, the present invention provides pharmaceutical compositions and methods for the treatment of a patient suffering from a disease or disorder associated with abnormal calcium levels, such as in the plasma, by the administration of a therapeutically effective amount of a compound capable of modulating the activity of a CaSR isoform. The term "patient" includes both human and other mammals.

"Pharmaceutical composition" refers to a composition comprising the compound and at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms. Examples of suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances. Prevention of the

action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. Examples of suitable carriers, diluents, solvents or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Examples of excipients include lactose, milk sugar, sodium citrate, calcium carbonate, dicalcium phosphate phosphate. Examples of disintegrating agents include starch, alginic acids and certain complex silicates. Examples of lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols.

"Pharmaceutically acceptable" means it is, within the scope of sound medical judgement, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.

"Pharmaceutically acceptable dosage forms" refers to dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.

"Pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, sulphamates, malonates, salicylates, propionates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyletartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quaternary ammonium salts, and the like. (See, for example S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 66: p.1-19 (1977) which is incorporated herein by reference.) Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. The sodium and potassium salts are preferred. Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide. Suitable amine base

addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, and dicyclohexylamine, and the like.

"Solid dosage form" means the dosage form of the compound of the invention is solid form, for example capsules, tablets, pills, powders, dragees or granules. In such solid dosage forms, the compound of the invention is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, (j) opacifying agents, (k) buffering agents, and agents which release the compound(s) of the invention in a certain part of the intestinal tract in a delayed manner.

The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the way together with the oil and fat make up the

emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

5 If desired, the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration
10 enhancers include dimethyl sulphoxide and related analogs.

 The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-
15 ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

 Solid compositions of may also be employed as fillers in soft and hard-filled gelatin capsules
20 using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.

 The pharmaceutical compositions can be administered in a suitable formulation to humans and animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, parenteral (including subcutaneous, intramuscular, intravenous, intradermal,
25 intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with for example the condition of the recipient.

 The formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared
30 by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

 "Formulations suitable for oral administration" may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-
35 water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tables may be prepared by compressing in a suitable machine the active

ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compounds moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled
5 release of the active ingredient therein.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

If desired, and for more effective distribution, the compounds can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as a biocompatible, biodegradable polymer
10 matrices (e.g. poly(d,l-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer. The compounds may be sterilized, for example, by filtration through a bacteria retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other
15 sterile injectable medium immediately before use.

Actual dosage levels of active ingredient in the compositions of the invention may be varied so as to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, on the route of administration, on the desired duration of treatment and
20 other factors.

Total daily dose of the compounds of this invention administered to a host in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body weight daily and preferably 0.01 to 10 mg/kg/day. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the
25 specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

The amount of each component administered is determined by the attending clinicians taking into consideration the etiology and severity of the disease, the patient's condition and age, the potency of each
30 component and other factors.

The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders,
35 granules and tablets of the kind previously described.

Gene Therapy and Transgenic Vectors

The present invention also relates to gene therapy of diseases or disorders associated with abnormal levels of calcium. As discussed above, a "vector" is any means for the transfer of a nucleic acid according to the invention into a host cell. Preferred vectors are viral vectors, such as retroviruses, herpes viruses, adenoviruses, and adeno-associated viruses. Thus, a gene encoding a CaSR, a CaSR isoform, a polypeptide domain fragment thereof, or a nucleic acid encoding a CaSR antisense sequence is introduced *in vivo*, *ex vivo*, or *in vitro* using a viral vector or through direct introduction of DNA. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both.

Expression vectors of the invention can be used, as pointed out above, both to transfect cells for screening or biological testing of modulators of CaSR activity, or for delivery of a CaSR nucleic acid, as described above, or CaSR antisense gene *in vivo* or *ex vivo* for gene therapy, *e.g.*, to increase or decrease the level of CaSR activity. A vector that expresses an anti-CaSR scFv can also be introduced using the techniques discussed below.

Viral vectors commonly used for *in vivo* or *ex vivo* targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art [see, *e.g.*, Miller and Rosman, *BioTechniques* 7:980-990 (1992)]. Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors which are used within the scope of the present invention lack at least one region which is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution (by other sequences, in particular by the inserted nucleic acid), partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed *in vitro* (on the isolated DNA) or *in situ*, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication defective virus retains the sequences of its genome which are necessary for encapsulating the viral particles.

DNA viral vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), vaccinia virus, and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not replication competent after introduction into a cell, and thus does not lead to a productive viral infection. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted. Examples of particular vectors include, but are not limited to, a

defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.* 2:320-330 (1991)], defective herpes virus vector lacking a glyco-protein L gene [Patent Publication RD 371005 A], or other defective herpes virus vectors [International Patent Publication No. WO 94/21807, published September 29, 1994; International Patent Publication No. WO 92/05263, published April 2, 1994]; an attenuated
5 adenovirus vector, such as the vector described by Stratford-Perricaudet et al. [*J. Clin. Invest.* 90:626-630 (1992); *see also* La Salle et al., *Science* 259:988-990 (1993)]; and a defective adeno-associated virus vector [Samulski et al., *J. Virol.* 61:3096-3101 (1987); Samulski et al., *J. Virol.* 63:3822-3828 (1989); Lebkowski et al., *Mol. Cell. Biol.* 8:3988-3996 (1988)].

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed
10 in conjunction with the viral vector, *e.g.*, adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon- γ (IFN- γ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors [*see, e.g.*, Wilson, *Nature Medicine* (1995)]. In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

15 Naturally, the invention contemplates delivery of a vector that will express a therapeutically effective amount of a CaSR, or an antisense thereto, for gene therapy applications. The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively,
20 therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

Any vector, viral or non-viral, of the invention will preferably be introduced *in vivo* in a pharmaceutically acceptable vehicle or carrier. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an
25 allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.

30 Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.

Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

Adenovirus vectors

In a preferred embodiment, the vector is an adenovirus vector. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types. Various serotypes of adenovirus exist. Of these serotypes, preference is given, within the scope of the present invention, to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g. Manhattan or A26/61 strain (ATCC VR-800), for example).

Preferably, the replication defective adenoviral vectors of the invention comprise the ITRs, an encapsidation sequence and the nucleic acid of interest. Still more preferably, at least the E1 region of the adenoviral vector is non-functional. The deletion in the E1 region preferably extends from nucleotides 455 to 3329 in the sequence of the Ad5 adenovirus (PvuII-BglII fragment) or 382 to 3446 (HinfII-Sau3A fragment). Other regions may also be modified, in particular the E3 region (WO95/02697), the E2 region (WO94/28938), the E4 region (WO94/28152, WO94/12649 and WO95/02697), or in any of the late genes L1-L5.

In a preferred embodiment, the adenoviral vector has a deletion in the E1 region (Ad 1.0). Examples of E1-deleted adenoviruses are disclosed in EP 185,573, the contents of which are incorporated herein by reference. In another preferred embodiment, the adenoviral vector has a deletion in the E1 and E4 regions (Ad 3.0). Examples of E1/E4-deleted adenoviruses are disclosed in WO95/02697 and WO96/22378, the contents of which are incorporated herein by reference. In still another preferred embodiment, the adenoviral vector has a deletion in the E1 region into which the E4 region and the nucleic acid sequence are inserted (see FR94 13355, the contents of which are incorporated herein by reference).

The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid which carries, inter alia, the DNA sequence of interest. The homologous recombination is effected following cotransfection of the adenovirus and plasmid into an appropriate cell line. The cell line which is employed should preferably (i) be transformable by the said elements, and (ii) contain the sequences which are able to complement the part of the genome of the replication defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. Examples of cell lines which may be used are the human embryonic kidney cell

line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains the left-hand portion of the genome of an Ad5 adenovirus (12%) integrated into its genome, and cell lines which are able to complement the E1 and E4 functions, as described in applications WO94/26914 and WO95/02697. Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.

Adeno-associated virus vectors

The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterised. It encompasses approximately 4700 bases and contains an inverted terminal repeat (ITR) region of approximately 145 bases at each end, which serves as an origin of replication for the virus. The remainder of the genome is divided into two essential regions which carry the encapsulation functions: the left-hand part of the genome, which contains the rep gene involved in viral replication and expression of the viral genes; and the right-hand part of the genome, which contains the cap gene encoding the capsid proteins of the virus.

The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (see WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488 528). These publications describe various AAV-derived constructs in which the rep and/or cap genes are deleted and replaced by a gene of interest, and the use of these constructs for transferring the said gene of interest *in vitro* (into cultured cells) or *in vivo*, (directly into an organism). The replication defective recombinant AAVs according to the invention can be prepared by cotransfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsulation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard techniques.

The invention also relates, therefore, to an AAV-derived recombinant virus whose genome encompasses a sequence encoding a nucleic acid encoding a CaSR flanked by the AAV ITRs. The invention also relates to a plasmid encompassing a sequence encoding a nucleic acid encoding a CaSR flanked by two ITRs from an AAV. Such a plasmid can be used as it is for transferring the nucleic acid sequence, with the plasmid, where appropriate, being incorporated into a liposomal vector (pseudovirus).

Retrovirus vectors

In another embodiment the gene can be introduced in a retroviral vector, *e.g.*, as described in

Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell 33:153; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., 1988, J. Virol. 62:1120; Temin et al., U.S. Patent No. 5,124,263; EP 453242, EP178220; Bernstein et al. Genet. Eng. 7 (1985) 235; McCormick, BioTechnology 3 (1985) 689; International Patent Publication No. WO 95/07358, published
5 March 16, 1995, by Dougherty et al.; and Kuo et al., 1993, Blood 82:845. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome includes two LTRs, an encapsulation sequence and three coding regions (*gag*, *pol* and *env*). In recombinant retroviral vectors, the *gag*, *pol* and *env* genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as, HIV,
10 MoMuLV ("murine Moloney leukaemia virus" MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") and Friend virus. Defective retroviral vectors are disclosed in WO95/02697.

In general, in order to construct recombinant retroviruses containing a nucleic acid sequence, a plasmid is constructed which contains the LTRs, the encapsulation sequence and the coding sequence.
15 This construct is used to transfect a packaging cell line, which cell line is able to supply in trans the retroviral functions which are deficient in the plasmid. In general, the packaging cell lines are thus able to express the *gag*, *pol* and *env* genes. Such packaging cell lines have been described in the prior art, in particular the cell line PA317 (US4,861,719); the PsiCRIP cell line (WO90/02806) and the GP+envAm-12 cell line (WO89/07150). In addition, the recombinant retroviral vectors can contain modifications
20 within the LTRs for suppressing transcriptional activity as well as extensive encapsulation sequences which may include a part of the *gag* gene (Bender et al., J. Virol. 61 (1987) 1639). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

Retroviral vectors can be constructed to function as infections particles or to undergo a single round of transfection. In the former case, the virus is modified to retain all of its genes except for those
25 responsible for oncogenic transformation properties, and to express the heterologous gene. Non-infectious viral vectors are prepared to destroy the viral packaging signal, but retain the structural genes required to package the co-introduced virus engineered to contain the heterologous gene and the packaging signals. Thus, the viral particles that are produced are not capable of producing additional virus.

30 Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

Non-viral vectors

Alternatively, the vector can be introduced *in vivo* by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic

cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* **84**:7413-7417 (1987); see Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* **85**:8027-8031 (1988); Ulmer et al., *Science* **259**:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* **337**:387-388 (1989)]. Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous genes into the specific organs *in vivo* has certain practical advantages.

Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, *e.g.*, hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (*e.g.*, International Patent Publication WO95/21931), peptides derived from DNA binding proteins (*e.g.*, International Patent Publication WO96/25508), or a cationic polymer (*e.g.*, International Patent Publication WO95/21931).

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [see, *e.g.*, Wu et al., *J. Biol. Chem.* **267**:963-967 (1992); Wu and Wu, *J. Biol. Chem.* **263**:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams et al., *Proc. Natl. Acad. Sci. USA* **88**:2726-2730 (1991)]. Receptor-mediated DNA delivery approaches can also be used [Curiel et al., *Hum. Gene Ther.* **3**:147-154 (1992); Wu and Wu, *J. Biol. Chem.* **262**:4429-4432 (1987)].

This invention provides several embodiments for specifically inhibiting CaSR activity in a patient suffering from a disease or disorder associated with abnormal calcium levels.

As a first embodiment, CaSR expression is inhibited by nucleic acids comprising a sequence complementary to the sequence encoding CaSR, or isoform thereof, and down-regulating or blocking its expression. A preferred embodiment comprises an antisense polynucleotide molecule. Preparation and use of antisense polynucleotides, DNA encoding antisense RNA molecules and use of oligo and genetic antisense is disclosed in WO 92/15680, the entire contents of which are incorporated herein by reference.

Antisense nucleic acids of the invention are preferably RNA capable of specifically hybridizing

with all or part of the sequence selected from the group consisting of SEQ ID No. 7, SEQ ID No. 9, and SEQ ID No. 11 or the corresponding messenger RNA. The antisense sequence of the present invention may be derived from DNA sequences whose expression in the cell produces RNA complementary to all or part of the CaSR. These antisense sequences can be prepared by expression of all or part of the sequence selected from the group consisting of SEQ ID No. 7, SEQ ID No. 9, and SEQ ID No. 11 in the opposite orientation (EP 140 308). Any length of the antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of the CaSR, or isoform thereof. Preferably, the antisense sequence is at least 20 nucleotides in length.

In another aspect of this preferred embodiment the nucleic acid encodes antisense RNA molecules. In this embodiment, the nucleic acid is operably linked to signals enabling expression of the nucleic acid sequence, and is introduced into a cell utilizing, preferably, recombinant vector constructs, which will express the antisense nucleic acid once the vector is introduced into the cell. Examples of suitable vectors includes plasmids, adenoviruses, adeno-associated viruses, retroviruses, and herpes viruses as described above.

Suitable expression signals include transcriptional promoter and termination sequences. Among the promoter sequences useful for practice of this invention are tetracycline-regulated transcriptional modulators and CMV, SV-40, E1a, MLP, and LTR promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US 5,168,062 and 5,385,839, the entire contents of which are incorporated herein by reference. The nucleic acid constructs of this invention are capable of down-regulating or blocking expression of a CaSR, or isoform thereof, and are delivered, in a preferred aspect of the invention, locally to cells capable of regulating calcium levels in a patient.

A second embodiment of the present invention's method of specifically inhibiting human CaSR activity, or an isoform thereof, at selected sites, comprises inhibiting CaSR function by expression of a nucleic acid sequence encoding an intracellular binding protein capable of selectively interacting with the CaSR, or isoform thereof, within a transfected cell. WO 94/29446 and WO 94/02610, the entire contents of which are incorporated herein by reference, disclose cellular transfection with genes encoding an intracellular binding protein. An intracellular binding protein includes any protein capable of selectively interacting, or binding, with a CaSR, or isoform thereof, in the cell in which it is expressed and of neutralizing the function of bound CaSR. Preferably, the intracellular binding protein is an antibody or a fragment of an antibody. More preferably, the antibody or fragment thereof binds the cytoplasmic domain of the CaSR. Most preferably, the intracellular binding protein is a single chain antibody capable of inhibiting cellular calcium sensing.

WO 94/02610 discloses preparation of antibodies and identification of the nucleic acid encoding a particular antibody. Using the CaSR or an isoform thereof, a monoclonal antibody specific for the cytoplasmic domain is prepared by according to techniques known to those skilled in the art. A vector comprising the nucleic acid encoding an intracellular binding protein, or a portion thereof, and capable of expression in a host cell is subsequently prepared for use in the method of this invention. Suitable vectors and methods of delivering nucleic acids encoding intracellular binding proteins to cells

containing a CaSR include those discussed above for delivery of antisense nucleic acids.

In a preferred aspect of this second embodiment, the nucleic acid sequence encoding a CaSR intracellular binding protein additionally comprises a sequence encoding a localization signal for targeting the intracellular binding protein to the cellular location of CaSR and/or a sequence enabling insertion of the intracellular binding protein in the plasma membrane. The localization signal or insertion sequence can be located anywhere on the intracellular binding protein, so long as it does not interfere with binding to the CaSR or isoform thereof. Examples of localization signals are disclosed in WO 94/02610. Preferably, the localization signal targets the intracellular binding protein to the plasma membrane.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention.

EXAMPLES

Material and Methods

General Materials and Methods:

Bacterial strain. The strain TG1 of *Escherichia coli* of the genotype supE, hsdD5, thi, D(lac-proAB), F'[tra D36 pro A⁺B⁺ lacI^q lacZDM15] may be used as a means to amplify and isolate the recombinant plasmids utilized.

It may be cultivated on:

LB medium: -NaCl (5 g/l) (Difco)
 -Bacto-tryptone (10 g/l) (Difco)
 -Yeast extract (5 g/l) (Difco)

This medium is rendered solid by the addition de 20 g/l of agar (Difco). Ampicillin (100 µg/ml) permits selection of the bacteria that have received the plasmids that carry the gene imparting resistance to this antibiotic as a marker.

Plasmids.

Bluescript series vectors (Stratagene), may used. These vectors permit cloning to be performed just like the pMTL series (Chambers et al.; Gene 1988, 68, pp 139-149).

In addition, the vectors pCDNA3 (Invitrogen) and derivative vectors (pSG42 and pCNW8), which permit the expression of proteins in mammal cells under the control of the CMV promoter, may be used.

Also, the vectors pCRII or pCR2.1 (Invitrogen), which permit cloning of PCR fragments, may be used.

The genetic engineering techniques used to clone and insert cDNAs into these plasmids employ routine protocols (Maniatis T. et al., "Molecular Cloning, a Laboratory Manual," Cold Spring Harbor

Laboratory, Cold Spring Harbor, N.Y., 1982; Ausubel F.M. et al. (eds.), "Current Protocols in Molecular Biology," John Wiley & Sons, New York, 1987).

Preparation of the plasmid DNA. Large quantities of DNA may be prepared using Promega's rapid DNA preparation kit in accordance with the manufacturer's instructions. Small quantities of DNA may be prepared in the following manner: bacteria containing the plasmid are cultivated for at least 4 hours in 2 ml of LB medium in a shaker with agitation. They are then centrifuged for 2 minutes at 14,000 rpm in Eppendorf tubes, then the concentrate is put back in suspension in 100 μ l of solution I (50 mM of glucose, 25 mM of Tris-HCl pH 8 buffer, 10 mM of EDTA pH 8), lysed with 200 μ l of solution II (0.2 M of NaOH, 1% SDS). The lysis solution is then neutralized with 150 μ l of solution III (3 M of potassium acetate, 11.5% (v/v) glacial acetic acid). After agitation of the tubes until a flocculent precipitate is obtained, 150 μ l of a mixture of phenol/chloroform (50% phenol and 50% chloroform saturated in water) is added, and the entire mixture is agitated for 30 seconds. The aqueous phase containing the DNA is recovered after centrifugation for 2 minutes at 14,000 rpm. The DNA is then precipitated via the addition of 0.5 volume of isopropanol, then centrifuged for 5 minutes at 14,000 rpm and air-dried in order to finally be dissolved in 20 μ l of TE-RNase (solution of 10 mM of Tris-HCl and 1 mM of EDTA with 50 μ g/ml of RNase).

Enzyme amplification of DNA by Polymerase Chain Reaction (PCR). PCR reactions may be carried out in a final volume of 100 μ l in the presence of the double stranded DNA, dNTP (0.2 mM), PCR buffer (10 mM of Tris-HCL pH 8.5, 1 mM of $MgCl_2$, 5 mM of KCl, gelatin 0.01%), 0.5 μ g of each of the oligonucleotides, and 2.5 IU of Ampli Taq DNA polymerase (Perkin Elmer) with or without formamide (5%). The mixture is covered with 2 drops of paraffin oil to limit evaporation of the sample. The equipment used may be Appligene's "Crocodile II." Unless otherwise specified, denaturation is effected at a temperature of 90°C for denaturation of the helix, a temperature for hybridization of the oligonucleotides to the denatured (single-stranded) DNA that is 5 to 10 degrees lower than the temperature for the separation of the oligonucleotides, and a temperature of 72°C for elongation by the enzyme. The fragments obtained by PCR, which are used for cloning, are systematically resequenced once they were cloned, so as to verify the absence of any mutations that might have occurred during the amplification.

The oligodeoxynucleotides may be chemically synthesized according to the phosphoramidite method by utilizing β -cyanoethyl protector groups. After synthesis, the protector groups are eliminated by treatment with ammonia, and two precipitations with butanol permit purification and concentration of the oligodeoxynucleotides. The DNA concentration may be determined by measuring the optical density at 260 nm.

Ligations. Ligation reactions may be carried out at +14°C for one night in a final volume of 10 μ l

in the presence of 100 to 200 ng of vector, 0.5 to 2 µg of insert, 40 IU of enzyme T4 DNA ligase (Biolabs), and a ligation buffer (50 mM of Tris-HCl pH 7.8; 10 mM of MgCl₂; 10 mM of DTT; 1 mM of ATP). The negative control is formed by the ligation of the vector in the absence of the insert.

The filling of the prominent 5' ends is carried out, as needed, before ligation via the Klenow fragment of DNA Polymerase I of *E. coli* (Biolabs) according to the supplier's specifications. The destruction of the prominent 3' ends is accomplished in the presence of DNA Polymerase of the T4 phage (Biolabs) used according to the manufacturer's recommendations.

Transformation of bacteria. The entire ligation volume (10 µl) may be used to transform bacteria, which may be rendered competent by the method of Chung et al. (1988, Proc. Natl. Acad. Sci. 86:2172-2175). The bacteria are placed in culture in a liquid LB medium for several hours in an incubator with agitation at 37°C until an OD of 0.6 was obtained at 600 nm. The medium is then centrifuged at 6,000 rpm for 10 mn. The bacteria are rendered competent by dissolving the bacterial concentrate in a volume of TSB (LB medium + 100 g/l of PEG 4000, 5% DMSO, 10 mM of MgCl₂, 10 mM of MgSO₄) corresponding to 1/10 of the volume of the medium of the initial culture. After incubation at 4°C for 30 to 60 minutes, 200 µl of bacteria are placed in contact with the ligation products for 15 minutes on ice. After the addition of 200 µl of LB [medium], the bacteria are incubated for 30 mn at 37°C, then spread out on an LB + ampicillin medium.

Separation and extraction of the DNA. The separation of the DNA is performed by electrophoresis as a function of their size. In order to do this, different gels are used depending on the size of the fragments to be separated:

-1% agarose gel (Gibco BRL) in a TBE buffer (90 mM of Tris base; 90 mM of borate; 2 mM of EDTA) to separate large DNA fragments (greater than 500 bp);

-2% NuSieve agarose gel (FMC Bioproducts) in a TBE buffer to separate small fragments (less than 500 bp).

Migration on agarose gel or on polyacrylamide gel is carried out in a TBE buffer and in the presence of a molecular weight marker (1 Kb ladder, Gibco BRL). The DNA was mixed with 1/10 of the deposit volume of blue (200 g/l of Ficoll, 0.5 g/l of bromophenol blue, 50 mM of EDTA) before being deposited on the gel. After migration at 100 Volts and staining with ethidium bromide (concentration 0.5 µg/ml of gel), the bands are viewed under a UV lamp.

Extraction of the DNA from the band of an agarose gel is carried out by means of electroelution as follows: the piece of gel containing the DNA fragments cut out with a scalpel and placed in a dialysis tube closed with two clamps and containing 100 to 500 µl of TBE. The entire mixture is placed in an electrophoresis tank, where it is subjected to an electrical field of 100 Volts. After being removed from the gel, the DNA is then purified by means of two extractions with phenol/chloroform followed by two

extractions with chloroform, then precipitated in the presence of 0.3 M of sodium acetate and 2.5 volume of absolute alcohol. After centrifugation (5 mn at 14,000 rpm), the DNA concentrate is dried and then dissolved in 20 µl of water.

Fluorescent sequencing of plasmid DNA. The sequencing may be carried out according to Sanger's method using 4 dideoxyribonucleotides possessing a different fluorescent marker. The incorporation of one of these dideoxyribonucleotides causes a halt in the replication by the polymerase Taq of the DNA to be sequenced. This reaction yields DNA fragments of various sizes, all of which are terminated at 3' by one of the 4 dideoxyribonucleotides. One µg of a plasmid and 4 picomoles of a primer are added to 9.5 µl of a "premix" supplied by Applied Biosystems under the trademark PRISM[®]. The final volume is 20 µl in order to perform a PCR for 25 cycles, broken down into a denaturation phase at 96°C for 30 seconds, a hybridization phase at 50°C for 15 seconds, and an elongation phase at 60°C for 4 minutes. DNA fragments obtained after amplification are purified on an exclusion column (Chromaspin-30 from Clontech) and are then dried in a Speed Vac. All of the dried material is dissolved in 5 µl of a mixture made up of 24 µl of EDTA (50 mM) and 120 µl of deionized formamide. After denaturation at 96°C for 3 minutes, 3 to 5 µl are deposited on an electrophoresis gel. The different DNA fragments are separated according to their size and then successively passed in front of a laser reader of the ABI 370 DNA sequencer (Applied Biosystems), where the different fluorescent chromophores are detected.

EXAMPLE 1: PCR amplification of CaSR splice variants

First-strand cDNA, isolated from total RNA from normal human adult tissue, was purchased from Invitrogen. The RNA was subsequently treated with DNase (RNase-free) to eliminate genomic DNA contamination. Ten micrograms (10ug) of the RNA is primed with an Oligo (dT) primer and reverse transcribed with MMLV reverse transcriptase. The reaction is stopped by incubating at 65°C for 10 minutes. The cDNA is in 40ul of RT buffer. (1xRT Buffer: 50mM Tris HCl, pH 8.3, 75 mM KCl, 3mM MgCl₂, 10mM DTT).

The following oligonucleotide primers were used to identify CaSR isoforms:

	<u>Primer</u>	<u>Sequence</u>	<u>Wild type CaSR position</u>	
5	1-AS	5'-CATGGGTCAATTCAGTGCAT-3'	3383 - 3403	(SEQ ID NO:1)
	3-AS	5'-GCCAGATCACACAGATGACAA-3'	2207 - 2227	(SEQ ID NO:2)
	4-AS	5'-GGCATAGACGTTGTAATACCC-3'	1525 - 1545	(SEQ ID NO:3)
	5-AS	5'-TGTGGACAGACTTCCTGGGAT-3'	1013 - 1033	(SEQ ID NO:4)
	5-S	5'-ATCCCAGGAAGTCTGTCCACA-3'	1013 - 1033	(SEQ ID NO:5)
10	7-S	5'-ACTCCTAGCTGTCTCATCCCT-3'	-44 - -24	(SEQ ID NO:6)

Splice variant CaSRc was amplified with Perkin Elmer's AmpliTaq Gold. The final reaction mix consisted of 10mM Tris-HCl, pH 8.3, 50mM KCl, 1.5mM MgCl₂, 0.001 (w/v) gelatin, 0.8mM dATP, 0.8mM dCTP, 0.8mM dGTP, 0.8mM dTTP, 2.5 Units AmpliTaq Gold, 0.4uM Primer 3-AS, 0.4uM Primer 5-S, and 2ul Invitrogen human kidney cDNA / 100ul reaction. Reaction conditions are: hold at 95°C for 9 minutes; 40 cycles of 94°C - 30 seconds, 60°C - 1 minute; and hold at 60°C for 10 minutes.

CaSRb was amplified using the same conditions as CaSRc, except that 0.4uM Primer 5-AS and 0.4uM Primer 7-S were used in place of Primers 3-AS and 5-S.

Splice variant CaSRd was amplified using the same components as CaSRc with the following exceptions: 0.4uM Primer 1-AS and 0.4uM Primer 7-S were used in place of Primers 3-AS and 5-S, and 3ul instead of 2ul of Invitrogen human kidney cDNA / 100ul reaction was used. Reaction conditions were: hold at 95°C for 9 minutes; 20 cycles of 94°C - 30 seconds, 64°C - 3 minutes; 20 cycles of 94°C - 30 seconds, 64°C - 3 minutes (increment 10 seconds / cycle); hold at 60°C for 10 minutes. 50ul of this reaction mix was then electrophoresed on a 1% agarose gel and the bands in the 3.0 - 3.4kb region were excised and extracted using Qiagen's Gel Extraction kit and eluted in 50ul ddH₂O. 1ul of this extract was used as a template for the next reaction which contained the same components as the previous reaction with the following exceptions: 0.4uM Primer 4-AS was used instead of Primer 1-AS, and the template was replaced. Reaction conditions for the first and second amplifications were identical.

All PCR products were cloned into pCR2.1 according to Invitrogen's protocols. Sequencing was performed with an automated DNA sequencer.

EXAMPLE 2: Expression of CaSRb and CaSRc in human kidney

The strategy of searching for CaSR splice variants involved the use of primer pairs to scan different parts of the sensor cDNA. Human kidney first strand cDNA was used as template and was

amplified with either primer pair 3AS/5S or 5AS/7S. Electrophoretic resolution of the PCR mixture obtained with primer pair 3AS/5S revealed the presence of a product with the expected size (1.2kb) of the wild type CaSR and one with lower molecular mass of approximately 1.0kb. The primer pair 5AS/7S also yielded two visible PCR products with estimated size of 1.0 and 0.7kb. The 1.0kb product corresponded to the expected size of the wild type CaSR. The PCR products from both primer pairs were ligated into pCR 2.1 and multiple clones were selected for analysis by restriction digestion with EcoR1 to release the insert. Clones bearing the putative wild type CaSR insert and those with smaller insert size were sequenced. The results of these experiments confirmed the presence of the correct CaSR sequence in the putative wild type clones. On the other hand, clones with shorter insert were found to contain either a deletion from nucleotide 186-495 or from nucleotide 1378-1608. The 186-495 deleted CaSR corresponds to CaSRb described originally in medullary thyroid carcinoma. The 1378-1608 deleted CaSR is designated as CaSRc (Figure 1). Unlike CaSRb, the deletion in CaSRc does not cause a shift in reading frame.

Example 3: Expression of CaSRd in human kidney

Following an initial PCR enrichment of human kidney first strand cDNA with primer pair 1AS/7S, products in the 3.0 - 3.4 kb range were gel purified and were amplified further with primer pair 4AS/7S. The PCR products were isolated by TA cloning and sequenced. One of these clones was found to contain a deletion from nucleotide 1075-1386 (Figure 1). The 1075-1386 deleted CaSR is designated CaSRd. No change in reading frame was detected in this alternatively spliced CaSR transcript.

Example 4: Stable expression of isoform CaSRd in HEK-293 cells

Full length CaSRd was cloned into the mammalian expression vector pCEP4 (from Invitrogen). The CaSRd DNA used for transfection was prepared using the Qiagen plasmid preparation kit. LipofectAMINE (Life Technologies, Inc.) was used as a carrier for transfection. Transfection of HEK-293 cells with CaSRd DNA was performed according to the general protocol described in the LipofectAMINE transfection kit. The CaSRd DNA and lipofectamine complex (1 ml) was overlaid onto HEK-293 cells (90% confluent) in 6 well plates. After 5 hr. at 37°C, 1 ml of DMEM containing 20% fetal bovine serum, penicillin and streptomycin was added to each well. After incubating at 37°C for 16 hours, the media was replaced with 2 ml of DMEM containing 10% bovine serum albumin, penicillin and streptomycin and the cultures were incubated further for 8 hours at 37°C. CaSRd transfectants were isolated by selection in the presence of hygromycin following limited dilution. The

cells in each well were trypsinized, and cultures were diluted in 100 ml of DMEM containing 10% fetal bovine serum, 200 ug/ml of hygromycin, penicillin and streptomycin. 1 ml aliquots of the diluted cultures were added to each well of several 24 well tissue culture plates. After 4 weeks in culture, wells containing a single colony were identified and each cell clone was expanded into a T75 flask. The expression of CaSRd in each cell clone was monitored by Northern analysis. A clone, 21/2 with the highest expression level was used for functional analysis as described below.

The function of isoform CaSRd was assayed by its ability to increase intracellular concentration in response to elevation in extracellular calcium concentrations and other agonists. The wild type receptor has been shown to increase intracellular calcium concentration when extracellular calcium concentrations were raised. Intracellular calcium was measured with the fluorescent indicator, fura-2 (from Molecular Probes). HEK-293 cells transfected with CaSRd was loaded in buffer containing 0.5uM fura-2, 20mM HEPES, pH 7.35, 0.1% BSA, 0.5mM CaCl₂, 0.5mM MgCl₂, 6.7mM KCl, 3mM glucose and 142mM NaCl for 45 min at 37°C. The cells were washed and resuspended to 2 x 10⁶ cells/ml in the loading buffer without fura-2. For intracellular calcium measurement, cells were placed in a quartz cuvette equilibrated at 37°C. Excitation monochrometers were centered at 340 and 380 nm with emission light collected at 505 nm. Different CaSR agonists were added to different final concentrations to activate the CaSR. Usually a final concentration of 10mM external CaCl₂ is sufficient to activate the wild type receptor maximally. Results indicated that CaSRd did not respond to agonists such as Ca⁺⁺, Mg⁺⁺ and neomycin but did respond to gadolinium (Table I). In the presence of a CaSR potentiating compound, NPS568 (WO 94/18959, Fox et al., (1993) J. Bone Min. Res. 8: S181; Abstract #260) CaSRd responded to calcium, magnesium and neomycin.

Table I

Effects of extracellular Ca⁺⁺, NPS568 and gadolinium on intracellular calcium level in CaSRd expressing HEK-293 cells

Increase in fura-2 fluorescence (cps x 10⁶)

	<u>Expt 1</u>	<u>Expt 2</u>
20mM Ca ²⁺	0.2	0
20mM Ca ²⁺ + 2uM NPS568	1.5	1.7
10uM NPS568	0.2	0.1
100uM gadolinium	2.0	

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become
5 apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for
10 description.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding an isoform of a human calcium sensing receptor, wherein the nucleic acid comprises about 2922 to about 3003 nucleotides and has a deletion of about 231 nucleotides when compared to the wild-type form of the receptor as depicted in SEQ ID NO:11.
- 5 2. The nucleic acid according to claim 1, wherein said deletion is from the region encoding the extracellular domain of the receptor.
3. The nucleic acid according to claim 2, wherein the deletion is from about nucleotides 1075-1386 of SEQ ID NO:11.
4. The nucleic acid according to claim 2, wherein the deletion is from about nucleotides 1378-1608
10 of SEQ ID NO:11.
5. The nucleic acid according to claim 2, wherein the deletion is from about nucleotides 1075-1608 of SEQ ID NO:11.
6. The nucleic acid according to claim 1, having at least one property selected from
 - a) it can be amplified by polymerase chain reaction (PCR) using an oligonucleotide primer
15 derived from SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11;
 - b) it hybridizes under stringent conditions with a nucleic acid having a nucleotide sequence as depicted in SEQ ID NO:7 or SEQ ID NO:9; and
 - c) it encodes a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:10, and allelic variants thereof.
- 20 7. The isolated nucleic acid of claim 2, wherein the isoform comprises an amino acid sequence as depicted in SEQ ID NO:8 or SEQ ID NO:10, or allelic variants thereof.
8. The isolated nucleic acid of claim 2 comprising a nucleotide sequence as depicted in SEQ ID NO:7 or SEQ ID NO:9, or allelic variants thereof.
9. The isolated nucleic acid of claim 1 wherein the nucleic acid can be amplified by polymerase
25 chain reaction (PCR) using an oligonucleotide primer selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:6.
10. A vector comprising the nucleic acid of claim 1.
11. The vector according to claim 10 wherein the nucleic acid is operatively associated with an expression control sequence permitting expression of the receptor in an expression competent
30 host cell.
12. The vector according to claim 11 selected from the group consisting of an RNA molecule, a plasmid DNA molecule, and a viral vector.
13. The vector according to claim 12 which is a plasmid DNA molecule.
14. The vector according to claim 12 which is a viral vector selected from the group consisting of
35

retrovirus, adenovirus, adeno-associated virus, herpes virus, and vaccinia virus.

15. A host cell transfected with the vector of claim 10.

16. A host cell transfected with the vector of claim 13.

17. The host cell of claim 15 selected from the group consisting of a bacterial cell, a yeast cell, and a mammalian cell.

18. A method for expressing an isoform of human calcium sensing receptor comprising:

a) culturing the host cell of claim 17 in culture medium under conditions permitting expression of the receptor; and

b) identifying cells expressing the receptor on their surface.

19. An isolated isoform of a human calcium sensing receptor, wherein the isoform comprises about 974 to about 1001 amino acids and has a deletion of about 77 amino acids when compared to the wild-type form of the receptor as depicted in SEQ ID NO:12.

20. The isoform according to claim 19, wherein said deletion is from the extracellular domain of the receptor.

21. The isoform according to claim 20, wherein the deletion is from about amino acids 358-462 of SEQ ID NO:12.

22. The isoform according to claim 20, wherein the deletion is from about amino acids 460-536 of SEQ ID NO:12.

23. The isoform according to claim 20, wherein the deletion is from about amino acids 358-536 of SEQ ID NO:12.

24. The isoform of claim 19, wherein the isoform comprises an amino acid sequence as depicted in SEQ ID NO:8 or SEQ ID NO:10, or allelic variants thereof.

25. A method of screening for agonists or antagonists of a CaSR isoform activity, the method comprising recombinantly producing a CaSR isoform, incubating a test sample with the CaSR isoform, measuring CaSR isoform activity and comparing the activity to that in the absence of the test sample.

26. The method according to claim 25, wherein the CaSR activity is its ability to influence intracellular calcium concentration.

27. The method according to claim 25, wherein the test sample is tested alone, in conjunction with an elevation in extracellular calcium concentration, or in the presence of other agonists or antagonists of CaSR isoform activity.

28. The method according to claim 26, wherein the intracellular calcium concentration is measured with a fluorescent indicator.

29. The method according to claim 28, wherein the indicator is fura-2.

30. A method of treating a patient suffering from a disease or disorder associated with abnormal

calcium levels, the method comprising the administration of a therapeutically effective amount of a compound capable of modulating the activity of a CaSR isoform.

31. The method according to claim 30, wherein the disease is hyperparathyroidism or osteoporosis.

5 32. The method according to claim 30, wherein the disease is Paget's disease, hypercalcemia malignancy, or hypertension.

33. The method according to claim 30, wherein the compound is an agonist or an antagonist of a CaSR isoform.

10 34. A method of increasing or decreasing the level of CaSR activity in a cell, the method comprising administering to the cell a nucleic acid capable of increasing or decreasing CaSR activity.

35. The method according to claim 34, wherein the cells are in a patient suffering from a disease or disorder associated with abnormal calcium levels.

36. The method according to claim 35, wherein the disease is hyperparathyroidism or osteoporosis.

15 37. The method according to claim 35, wherein the disease is Paget's disease, hypercalcemia malignancy, or hypertension.

38. The method according to claim 35, wherein the nucleic acid is in a vector.

20 39. The method according to claim 38, wherein the nucleic acid encodes an isoform of a human calcium sensing receptor, wherein the nucleic acid comprises about 2922 to about 3003 nucleotides and has a deletion of about 231 nucleotides when compared to the wild-type form of the receptor as depicted in SEQ ID NO:11.

40. The method according to claim 38, wherein said vector is selected from the group consisting of plasmids, retroviruses, herpes simplex viruses, adeno-associated viruses, adenoviruses, and vaccinia viruses.

25 41. The method according to claim 27, wherein the nucleic acid encodes an intracellular binding protein capable of binding a CaSR, or an isoform thereof.

42. The method according to claim 41, wherein the intracellular binding protein is an antibody or fragment thereof.

43. The method according to claim 42, wherein the antibody or fragment thereof binds the cytoplasmic domain of a CaSR.

30 44. The method according to claim 43, wherein the antibody or fragment thereof is a single chain antibody.

45. The method according to claim 41, wherein said nucleic acid further comprises a sequence encoding a localization signal for targeting the intracellular binding protein to the cellular location of a CaSR.

35 46. The method according to claim 45, wherein said localization signal is specific for the plasma

membrane.

47. The method according to claim 34, wherein said nucleic acid encodes an antisense molecule complementary to the sequence encoding a CaSR and capable of selectively inhibiting the expression of said sequence.
- 5 48. The method according to claim 47, wherein said antisense molecule is at least about 20 nucleotides in length.
49. An antigenic polypeptide comprising an an epitope and/or sequence not present in the wild-type CaSR, wherein said polypeptide elicits antibodies which bind to a CaSR isoform.
- 10 50. An antibody that specifically recognizes an isoform of CaSR, and does not bind the wild-type CaSR

ABSTRACT OF THE INVENTION


5

The present invention relates to isoforms of a human calcium sensing receptor, and to the genes encoding these isoforms. The invention further relates to methods of screening for agonists or antagonists of the isoforms, particularly with respect to calcium receptor activity, to diagnostic uses of these isoforms and to therapeutic uses of the agonists or antagonists. The invention also relates to gene

10


therapy using the genes encoding the receptor isoforms or molecules capable of down-regulating receptor activity, such as antisense sequences.

FIG. 1



DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

UNITED STATES OF AMERICA



As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and
for which a patent is sought on the invention entitled:

ISOFORMS OF HUMAN CALCIUM SENSING RECEPTOR

and the specification of which ☐ is attached hereto (Attorney Docket No. **A2996A US**)
(check one) ☒ was filed on **January 30, 2001** as U.S. Application Number **09/744,788**
and was amended on _____ (if applicable).
☐ was described and claimed in PCT Int'l Application Number _____ filed on _____
and as amended under PCT Article 19 on _____ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including
the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be
material to patentability as defined in 37 C.F.R. 1.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at
least one other country other than the United States of America, listed below and having a filing date before that of the
application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's
certificate having a filing date before that of the application on which priority is claimed:

Foreign
Priority: Number Country Day/Month/Year Filed

Prior
Foreign
Appln(s): Number Country Day/Month/Year Filed

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional
application(s) listed below:

60/094,702 **July 30, 1998**
Number Filing Date

☐ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or
international application designating the United States listed below and, insofar as the subject matter of each of the
claims of this application is not disclosed in the prior United States application in the manner provided by the first
paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material
to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing
date of the prior application and the national or PCT international filing date of this application.

Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our
attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and
Trademark Office connected therewith:

Customer No.: 005487

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and
the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful
false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

00744755 . 012402

1-001. Full name: Kin T. Yu

Signature: *Kin T. Yu*

Date: June 20th 2001

Country of Citizenship: U.S.A.

Residence: Chalfont, PA USA PA
(City and State/City and Country only)

P. O. Address 1024 Hickory Ridge Drive
Chalfont, PA 18914

2. Full name: Richard F. Labaudiniere

Signature: _____

Date: _____

Country of Citizenship: France

Residence: Collegeville, PA USA
(City and State/City and Country only)

P. O. Address 220 Richard Way
Collegeville, PA 19426

3. Full name: Larry W. Thrower

Signature: _____

Date: _____

Country of Citizenship: United States

Residence: Roversford, PA USA
(City and State/City and Country only)

P. O. Address 1204 Brooke Drive
Roversford, PA 19468

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code EMC-G1
Bridgewater, NJ 08807-0800
Telephone (908) 231-
Telefax (908) 231-2626

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ISOFORMS OF HUMAN CALCIUM SENSING RECEPTOR

and the specification of which
(check one)

- ☐ is attached hereto (Attorney Docket No. **A2996A US**)
☒ was filed on **January 30, 2001** as U.S. Application Number **09/744,788**
 and was amended on _____ (if applicable).
☐ was described and claimed in PCT Int'l Application Number _____ filed on _____
 and as amended under PCT Article 19 on _____ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	Number _____	Country _____	Day/Month/Year Filed _____
----------------------	--------------	---------------	----------------------------

Prior Foreign Appln(s):	Number _____	Country _____	Day/Month/Year Filed _____
-------------------------------	--------------	---------------	----------------------------

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

60/094,702	July 30, 1998
Number	Filing Date

☐ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No. _____	Filing Date _____	Status (Patented, Pending) _____
------------------------------	-------------------	----------------------------------

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer No.: 005487

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☒ Additional names and signatures are attached.

2-00

1. Full name: Kin T. Yu

Signature: _____

Date: _____

Country of Citizenship: Australia

Residence: Limerick, PA USA
(City and State/City and Country only)

P. O. Address: 26 Galie Way
Limerick, PA 19468

2. Full name: Richard F. Labaudiniere

Signature: *Richard F. Labaudiniere*

Date: October 24, 2001

Country of Citizenship: France

Residence: Collegeville, PA USA Sherborn, MA USA MA
(City and State/City and Country only)

P. O. Address: 220 Richard Way 258 Western Avenue
Collegeville, PA 19426 Sherborn, MA 01770

(RL-10/24/01)

3-00

3. Full name: Larry W. Thrower

Signature: _____

Date: _____

Country of Citizenship: United States

Residence: Royersford, PA USA PA
(City and State/City and Country only)

P. O. Address: 1204 Brooke Drive
Royersford, PA 19468

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code EMC-G1
Bridgewater, NJ 08807-0800
Telephone (908) 231-
Telefax (908) 231-2626

SEQUENCE LISTING

<110> Yu, Kin Tak
Thrower, Larry W.
Labaudiniere, Richard F.

<120> ISOFORMS OF HUMAN CALCIUM SENSING RECEPTOR

<130> A2996-US

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Homo sapiens

<400> 1

catgggtcaa ttcactgtca t

21

<210> 2

<211> 21

<212> DNA

<213> Homo sapiens

<400> 2

gccagatcac acagatgaca a

21

<210> 3

<211> 21

<212> DNA

<213> Homo sapiens

<400> 3

ggcatagacg ttgtaatacc c

21

<210> 4

<211> 21

<212> DNA

<213> Homo sapiens

<400> 4
tgtggacaga cttcctggga t

21

<210> 5
<211> 21
<212> DNA
<213> Homo sapiens

<400> 5
atcccaggaa gtctgtccac a

21

<210> 6
<211> 21
<212> DNA
<213> Homo sapiens

<400> 6
actcctagct gtctcatccc t

21

<210> 7
<211> 3003
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(3003)

<400> 7
atg gca ttt tat agc tgc tgc tgg gtc ctc ttg gca ctc acc tgg cac 48
Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
1 5 10 15

acc tct gcc tac ggg cca gac cag cga gcc caa aag aag ggg gac att 96
Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
20 25 30

atc ctt ggg ggg ctc ttt cct att cat ttt gga gta gca gct aaa gat 144
Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
35 40 45

caa gat ctc aaa tca agg ccg gag tct gtg gaa tgt atc agg tat aat 192
Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
50 55 60

ttc cgt ggg ttt cgc tgg tta cag gct atg ata ttt gcc ata gag gag	240
Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu	
65 70 75 80	
ata aac agc agc cca gcc ctt ctt ccc aac ttg acg ctg gga tac agg	288
Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg	
85 90 95	
ata ttt gac act tgc aac acc gtt tct aag gcc ttg gaa gcc acc ctg	336
Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu	
100 105 110	
agt ttt gtt gct caa aac aaa att gat tct ttg aac ctt gat gag ttc	384
Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe	
115 120 125	
tgc aac tgc tca gag cac att ccc tct acg att gct gtg gtg gga gca	432
Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala	
130 135 140	
act ggc tca ggc gtc tcc acg gca gtg gca aat ctg ctg ggg ctc ttc	480
Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe	
145 150 155 160	
tac att ccc cag gtc agt tat gcc tcc tcc agc aga ctc ctc agc aac	528
Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn	
165 170 175	
aag aat caa ttc aag tct ttc ctc cga acc atc ccc aat gat gag cac	576
Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His	
180 185 190	
cag gcc act gcc atg gca gac atc atc gag tat ttc cgc tgg aac tgg	624
Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp	
195 200 205	
gtg ggc aca att gca gct gat gac gac tat ggg cgg ccg ggg att gag	672
Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu	
210 215 220	
aaa ttc cga gag gaa gct gag gaa agg gat atc tgc atc gac ttc agt	720
Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser	
225 230 235 240	
gaa ctc atc tcc cag tac tct gat gag gaa gag atc cag cat gtg gta	768
Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val	
245 250 255	

gag gtg att caa aat tcc acg gcc aaa gtc atc gtg gtt ttc tcc agt	816
Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser	
260 265 270	
ggc cca gat ctt gag ccc ctc atc aag gag att gtc cgg cgc aat atc	864
Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile	
275 280 285	
acg ggc aag atc tgg ctg gcc agc gag gcc tgg gcc agc tcc tcc ctg	912
Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu	
290 295 300	
atc gcc atg cct cag tac ttc cac gtg gtt ggc ggc acc att gga ttc	960
Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe	
305 310 315 320	
gct ctg aag gct ggg cag atc cca ggc ttc cgg gaa ttc ctg aag aag	1008
Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys	
325 330 335	
gtc cat ccc agg aag tct gtc cac aat ggt ttt gcc aag gag ttt tgg	1056
Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp	
340 345 350	
gaa gaa aca ttt aac tgc cac ctc caa gaa ggt gca aaa gga cct tta	1104
Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu	
355 360 365	
cct gtg gac acc ttt ctg aga ggt cac gaa gaa agt ggc gac agg ttt	1152
Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe	
370 375 380	
agc aac agc tcg aca gcc ttc cga ccc ctc tgt aca ggg gat gag aac	1200
Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn	
385 390 395 400	
atc agc agt gtc gag acc cct tac ata gat tac acg cat tta cgg ata	1248
Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile	
405 410 415	
tcc tac aat gtg tac tta gca gtc tac tcc att gcc cac gcc ttg caa	1296
Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln	
420 425 430	
gat ata tat acc tgc tta cct ggg aga ggg ctc ttc acc aat ggc tcc	1344
Asp Ile Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser	
435 440 445	

tgt gca gac atc aag aaa gtt gag gcg tgg cag gtg ccc ttc tcc aac	1392
Cys Ala Asp Ile Lys Lys Val Glu Ala Trp Gln Val Pro Phe Ser Asn	
450 455 460	
tgc agc cga gac tgc ctg gca ggg acc agg aaa ggg atc att gag ggg	1440
Cys Ser Arg Asp Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly	
465 470 475 480	
gag ccc acc tgc tgc ttt gag tgt gtg gag tgt cct gat ggg gag tat	1488
Glu Pro Thr Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr	
485 490 495	
agt gat gag aca gat gcc agt gcc tgt aac aag tgc cca gat gac ttc	1536
Ser Asp Glu Thr Asp Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe	
500 505 510	
tgg tcc aat gag aac cac acc tcc tgc att gcc aag gag atc gag ttt	1584
Trp Ser Asn Glu Asn His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe	
515 520 525	
ctg tcg tgg acg gag ccc ttt ggg atc gca ctc acc ctc ttt gcc gtg	1632
Leu Ser Trp Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val	
530 535 540	
ctg ggc att ttc ctg aca gcc ttt gtg ctg ggt gtg ttt atc aag ttc	1680
Leu Gly Ile Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe	
545 550 555 560	
cgc aac aca ccc att gtc aag gcc acc aac cga gag ctc tcc tac ctc	1728
Arg Asn Thr Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu	
565 570 575	
ctc ctc ttc tcc ctg ctc tgc tgc ttc tcc agc tcc ctg ttc ttc atc	1776
Leu Leu Phe Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile	
580 585 590	
ggg gag ccc cag gac tgg acg tgc cgc ctg cgc cag ccg gcc ttt ggc	1824
Gly Glu Pro Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly	
595 600 605	
atc agc ttc gtg ctc tgc atc tca tgc atc ctg gtg aaa acc aac cgt	1872
Ile Ser Phe Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg	
610 615 620	
gtc ctc ctg gtg ttt gag gcc aag atc ccc acc agc ttc cac cgc aag	1920
Val Leu Leu Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys	
625 630 635 640	

tgg tgg ggg ctc aac ctg cag ttc ctg ctg gtt ttc ctc tgc acc ttc	1968
Trp Trp Gly Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe	
645 650 655	
atg cag att gtc atc tgt gtg atc tgg ctc tac acc gcg ccc ccc tca	2016
Met Gln Ile Val Ile Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser	
660 665 670	
agc tac cgc aac cag gag ctg gag gat gag atc atc ttc atc acg tgc	2064
Ser Tyr Arg Asn Gln Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys	
675 680 685	
cac gag ggc tcc ctc atg gcc ctg ggc ttc ctg atc ggc tac acc tgc	2112
His Glu Gly Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys	
690 695 700	
ctg ctg gct gcc atc tgc ttc ttc ttt gcc ttc aag tcc cgg aag ctg	2160
Leu Leu Ala Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu	
705 710 715 720	
ccg gag aac ttc aat gaa gcc aag ttc atc acc ttc agc atg ctc atc	2208
Pro Glu Asn Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile	
725 730 735	
ttc ttc atc gtc tgg atc tcc ttc att cca gcc tat gcc agc acc tat	2256
Phe Phe Ile Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr	
740 745 750	
ggc aag ttt gtc tct gcc gta gag gtg att gcc atc ctg gca gcc agc	2304
Gly Lys Phe Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser	
755 760 765	
ttt ggc ttg ctg gcg tgc atc ttc ttc aac aag atc tac atc att ctc	2352
Phe Gly Leu Leu Ala Cys Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu	
770 775 780	
ttc aag cca tcc cgc aac acc atc gag gag gtg cgt tgc agc acc gca	2400
Phe Lys Pro Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala	
785 790 795 800	
gct cac gct ttc aag gtg gct gcc cgg gcc acg ctg cgc cgc agc aac	2448
Ala His Ala Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn	
805 810 815	
gtc tcc cgc aag cgg tcc agc agc ctt gga ggc tcc acg gga tcc acc	2496
Val Ser Arg Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr	
820 825 830	

cct tcc tcc tcc atc agc agc aag agc aac agc gaa gac cca ttc cca	2544
Pro Ser Ser Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro	
835 840 845	
cag ccc gag agg cag aag cag cag cag ccg ctg gcc cta acc cag caa	2592
Gln Pro Glu Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln	
850 855 860	
gag cag cag cag cag ccc ctg acc ctc cca cag cag caa cga tct cag	2640
Glu Gln Gln Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln	
865 870 875 880	
cag cag ccc aga tgc aag cag aag gtc atc ttt ggc agc ggc acg gtc	2688
Gln Gln Pro Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val	
885 890 895	
acc ttc tca ctg agc ttt gat gag cct cag aag aac gcc atg gcc cac	2736
Thr Phe Ser Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His	
900 905 910	
agg aat tct acg cac cag aac tcc ctg gag gcc cag aaa agc agc gat	2784
Arg Asn Ser Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp	
915 920 925	
acg ctg acc cga cac cag cca tta ctc ccg ctg cag tgc ggg gaa acg	2832
Thr Leu Thr Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu Thr	
930 935 940	
gac tta gat ctg acc gtc cag gaa aca ggt ctg caa gga cct gtg ggt	2880
Asp Leu Asp Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly	
945 950 955 960	
gga gac cag cgg cca gag gtg gag gac cct gaa gag ttg tcc cca gca	2928
Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala	
965 970 975	
ctt gta gtg tcc agt tca cag agc ttt gtc atc agt ggt gga ggc agc	2976
Leu Val Val Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser	
980 985 990	
act gtt aca gaa aac gta gtg aat tca	3003
Thr Val Thr Glu Asn Val Val Asn Ser	
995 1000	

<210> 8

<211> 1001

<212> PRT

<213> Homo sapiens

<400> 8

```

Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
  1             5             10             15

Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
      20             25             30

Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
      35             40             45

Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
      50             55             60

Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
      65             70             75             80

Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg
      85             90             95

Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu
      100            105            110

Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe
      115            120            125

Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala
      130            135            140

Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe
      145            150            155            160

Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn
      165            170            175

Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His
      180            185            190

Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp
      195            200            205

Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu
      210            215            220

Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser
      225            230            235            240

```

Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val
 245 250 255
 Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser
 260 265 270
 Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile
 275 280 285
 Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu
 290 295 300
 Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe
 305 310 315 320
 Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys
 325 330 335
 Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp
 340 345 350
 Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu
 355 360 365
 Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe
 370 375 380
 Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn
 385 390 395 400
 Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile
 405 410 415
 Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln
 420 425 430
 Asp Ile Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser
 435 440 445
 Cys Ala Asp Ile Lys Lys Val Glu Ala Trp Gln Val Pro Phe Ser Asn
 450 455 460
 Cys Ser Arg Asp Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly
 465 470 475 480
 Glu Pro Thr Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr
 485 490 495

Ser Asp Glu Thr Asp Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe
 500 505 510

Trp Ser Asn Glu Asn His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe
 515 520 525

Leu Ser Trp Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val
 530 535 540

Leu Gly Ile Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe
 545 550 555 560

Arg Asn Thr Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu
 565 570 575

Leu Leu Phe Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile
 580 585 590

Gly Glu Pro Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly
 595 600 605

Ile Ser Phe Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg
 610 615 620

Val Leu Leu Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys
 625 630 635 640

Trp Trp Gly Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe
 645 650 655

Met Gln Ile Val Ile Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser
 660 665 670

Ser Tyr Arg Asn Gln Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys
 675 680 685

His Glu Gly Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys
 690 695 700

Leu Leu Ala Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu
 705 710 715 720

Pro Glu Asn Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile
 725 730 735

Phe Phe Ile Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr
 740 745 750

Gly Lys Phe Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser
 755 760 765

Phe Gly Leu Leu Ala Cys Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu
 770 775 780

Phe Lys Pro Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala
 785 790 795 800

Ala His Ala Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn
 805 810 815

Val Ser Arg Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr
 820 825 830

Pro Ser Ser Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro
 835 840 845

Gln Pro Glu Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln
 850 855 860

Glu Gln Gln Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln
 865 870 875 880

Gln Gln Pro Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val
 885 890 895

Thr Phe Ser Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His
 900 905 910

Arg Asn Ser Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp
 915 920 925

Thr Leu Thr Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu Thr
 930 935 940

Asp Leu Asp Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly
 945 950 955 960

Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala
 965 970 975

Leu Val Val Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser
 980 985 990

Thr Val Thr Glu Asn Val Val Asn Ser
 995 1000

<210> 9
 <211> 2922
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)..(2922)

<400> 9

atg gca ttt tat agc tgc tgc tgg gtc ctc ttg gca ctc acc tgg cac	48
Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His	
1 5 10 15	
acc tct gcc tac ggg cca gac cag cga gcc caa aag aag ggg gac att	96
Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile	
20 25 30	
atc ctt ggg ggg ctc ttt cct att cat ttt gga gta gca gct aaa gat	144
Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp	
35 40 45	
caa gat ctc aaa tca agg ccg gag tct gtg gaa tgt atc agg tat aat	192
Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn	
50 55 60	
ttc cgt ggg ttt cgc tgg tta cag gct atg ata ttt gcc ata gag gag	240
Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu	
65 70 75 80	
ata aac agc agc cca gcc ctt ctt ccc aac ttg acg ctg gga tac agg	288
Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg	
85 90 95	
ata ttt gac act tgc aac acc gtt tct aag gcc ttg gaa gcc acc ctg	336
Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu	
100 105 110	
agt ttt gtt gct caa aac aaa att gat tct ttg aac ctt gat gag ttc	384
Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe	
115 120 125	
tgc aac tgc tca gag cac att ccc tct acg att gct gtg gtg gga gca	432
Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala	
130 135 140	

gtc cat ccc agg aag tct gtc cac aat ggt ttt gcc aag gag ttt tgg	1056
Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp	
340 345 350	
 gaa gaa aca ttt aac tgc cac cta cgg cat cta aac ttt aca aac aat	1104
Glu Glu Thr Phe Asn Cys His Leu Arg His Leu Asn Phe Thr Asn Asn	
355 360 365	
 atg ggg gag cag gtg acc ttt gat gag tgt ggt gac ctg gtg ggg aac	1152
Met Gly Glu Gln Val Thr Phe Asp Glu Cys Gly Asp Leu Val Gly Asn	
370 375 380	
 tat tcc atc atc aac tgg cac ctc tcc cca gag gat ggc tcc atc gtg	1200
Tyr Ser Ile Ile Asn Trp His Leu Ser Pro Glu Asp Gly Ser Ile Val	
385 390 395 400	
 ttt aag gaa gtc ggg tat tac aac gtc tat gcc aag aag gga gaa aga	1248
Phe Lys Glu Val Gly Tyr Tyr Asn Val Tyr Ala Lys Lys Gly Glu Arg	
405 410 415	
 ctc ttc atc aac gag gag aaa atc ctg tgg agt ggt ttc tcc agg gag	1296
Leu Phe Ile Asn Glu Glu Lys Ile Leu Trp Ser Gly Phe Ser Arg Glu	
420 425 430	
 gtg ccc ttc tcc aac tgc agc cga gac tgc ctg gca ggg acc agg aaa	1344
Val Pro Phe Ser Asn Cys Ser Arg Asp Cys Leu Ala Gly Thr Arg Lys	
435 440 445	
 ggg atc att gag ggg gag ccc acc tgc tgc ttt gag tgt gtg gag tgt	1392
Gly Ile Ile Glu Gly Glu Pro Thr Cys Cys Phe Glu Cys Val Glu Cys	
450 455 460	
 cct gat ggg gag tat agt gat gag aca gat gcc agt gcc tgt aac aag	1440
Pro Asp Gly Glu Tyr Ser Asp Glu Thr Asp Ala Ser Ala Cys Asn Lys	
465 470 475 480	
 tgc cca gat gac ttc tgg tcc aat gag aac cac acc tcc tgc att gcc	1488
Cys Pro Asp Asp Phe Trp Ser Asn Glu Asn His Thr Ser Cys Ile Ala	
485 490 495	
 aag gag atc gag ttt ctg tcg tgg acg gag ccc ttt ggg atc gca ctc	1536
Lys Glu Ile Glu Phe Leu Ser Trp Thr Glu Pro Phe Gly Ile Ala Leu	
500 505 510	
 acc ctc ttt gcc gtg ctg ggc att ttc ctg aca gcc ttt gtg ctg ggt	1584
Thr Leu Phe Ala Val Leu Gly Ile Phe Leu Thr Ala Phe Val Leu Gly	
515 520 525	

gtg ttt atc aag ttc cgc aac aca ccc att gtc aag gcc acc aac cga	1632
Val Phe Ile Lys Phe Arg Asn Thr Pro Ile Val Lys Ala Thr Asn Arg	
530 535 540	
gag ctc tcc tac ctc ctc ctc ttc tcc ctg ctc tgc tgc ttc tcc agc	1680
Glu Leu Ser Tyr Leu Leu Leu Phe Ser Leu Leu Cys Cys Phe Ser Ser	
545 550 555 560	
tcc ctg ttc ttc atc ggg gag ccc cag gac tgg acg tgc cgc ctg cgc	1728
Ser Leu Phe Phe Ile Gly Glu Pro Gln Asp Trp Thr Cys Arg Leu Arg	
565 570 575	
cag ccg gcc ttt ggc atc agc ttc gtg ctc tgc atc tca tgc atc ctg	1776
Gln Pro Ala Phe Gly Ile Ser Phe Val Leu Cys Ile Ser Cys Ile Leu	
580 585 590	
gtg aaa acc aac cgt gtc ctc ctg gtg ttt gag gcc aag atc ccc acc	1824
Val Lys Thr Asn Arg Val Leu Leu Val Phe Glu Ala Lys Ile Pro Thr	
595 600 605	
agc ttc cac cgc aag tgg tgg ggg ctc aac ctg cag ttc ctg ctg gtt	1872
Ser Phe His Arg Lys Trp Trp Gly Leu Asn Leu Gln Phe Leu Leu Val	
610 615 620	
ttc ctc tgc acc ttc atg cag att gtc atc tgt gtg atc tgg ctc tac	1920
Phe Leu Cys Thr Phe Met Gln Ile Val Ile Cys Val Ile Trp Leu Tyr	
625 630 635 640	
acc gcg ccc ccc tca agc tac cgc aac cag gag ctg gag gat gag atc	1968
Thr Ala Pro Pro Ser Ser Tyr Arg Asn Gln Glu Leu Glu Asp Glu Ile	
645 650 655	
atc ttc atc acg tgc cac gag ggc tcc ctc atg gcc ctg ggc ttc ctg	2016
Ile Phe Ile Thr Cys His Glu Gly Ser Leu Met Ala Leu Gly Phe Leu	
660 665 670	
atc ggc tac acc tgc ctg ctg gct gcc atc tgc ttc ttc ttt gcc ttc	2064
Ile Gly Tyr Thr Cys Leu Leu Ala Ala Ile Cys Phe Phe Phe Ala Phe	
675 680 685	
aag tcc cgg aag ctg ccg gag aac ttc aat gaa gcc aag ttc atc acc	2112
Lys Ser Arg Lys Leu Pro Glu Asn Phe Asn Glu Ala Lys Phe Ile Thr	
690 695 700	
ttc agc atg ctc atc ttc ttc atc gtc tgg atc tcc ttc att cca gcc	2160
Phe Ser Met Leu Ile Phe Phe Ile Val Trp Ile Ser Phe Ile Pro Ala	
705 710 715 720	

tat gcc agc acc tat ggc aag ttt gtc tct gcc gta gag gtg att gcc	2208
Tyr Ala Ser Thr Tyr Gly Lys Phe Val Ser Ala Val Glu Val Ile Ala	
725 730 735	
atc ctg gca gcc agc ttt ggc ttg ctg gcg tgc atc ttc ttc aac aag	2256
Ile Leu Ala Ala Ser Phe Gly Leu Leu Ala Cys Ile Phe Phe Asn Lys	
740 745 750	
atc tac atc att ctc ttc aag cca tcc cgc aac acc atc gag gag gtg	2304
Ile Tyr Ile Ile Leu Phe Lys Pro Ser Arg Asn Thr Ile Glu Glu Val	
755 760 765	
cgt tgc agc acc gca gct cac gct ttc aag gtg gct gcc cgg gcc acg	2352
Arg Cys Ser Thr Ala Ala His Ala Phe Lys Val Ala Ala Arg Ala Thr	
770 775 780	
ctg cgc cgc agc aac gtc tcc cgc aag cgg tcc agc agc ctt gga ggc	2400
Leu Arg Arg Ser Asn Val Ser Arg Lys Arg Ser Ser Ser Leu Gly Gly	
785 790 795 800	
tcc acg gga tcc acc cct tcc tcc tcc atc agc agc aag agc aac agc	2448
Ser Thr Gly Ser Thr Pro Ser Ser Ser Ile Ser Ser Lys Ser Asn Ser	
805 810 815	
gaa gac cca ttc cca cag ccc gag agg cag aag cag cag cag ccg ctg	2496
Glu Asp Pro Phe Pro Gln Pro Glu Arg Gln Lys Gln Gln Gln Pro Leu	
820 825 830	
gcc cta acc cag caa gag cag cag cag cag ccc ctg acc ctc cca cag	2544
Ala Leu Thr Gln Gln Glu Gln Gln Gln Gln Pro Leu Thr Leu Pro Gln	
835 840 845	
cag caa cga tct cag cag cag ccc aga tgc aag cag aag gtc atc ttt	2592
Gln Gln Arg Ser Gln Gln Gln Pro Arg Cys Lys Gln Lys Val Ile Phe	
850 855 860	
ggc agc ggc acg gtc acc ttc tca ctg agc ttt gat gag cct cag aag	2640
Gly Ser Gly Thr Val Thr Phe Ser Leu Ser Phe Asp Glu Pro Gln Lys	
865 870 875 880	
aac gcc atg gcc cac agg aat tct acg cac cag aac tcc ctg gag gcc	2688
Asn Ala Met Ala His Arg Asn Ser Thr His Gln Asn Ser Leu Glu Ala	
885 890 895	
cag aaa agc agc gat acg ctg acc cga cac cag cca tta ctc ccg ctg	2736
Gln Lys Ser Ser Asp Thr Leu Thr Arg His Gln Pro Leu Leu Pro Leu	
900 905 910	

cag tgc ggg gaa acg gac tta gat ctg acc gtc cag gaa aca ggt ctg 2784
 Gln Cys Gly Glu Thr Asp Leu Asp Leu Thr Val Gln Glu Thr Gly Leu
 915 920 925

caa gga cct gtg ggt gga gac cag cgg cca gag gtg gag gac cct gaa 2832
 Gln Gly Pro Val Gly Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu
 930 935 940

gag ttg tcc cca gca ctt gta gtg tcc agt tca cag agc ttt gtc atc 2880
 Glu Leu Ser Pro Ala Leu Val Val Ser Ser Gln Ser Phe Val Ile
 945 950 955 960

agt ggt gga ggc agc act gtt aca gaa aac gta gtg aat tca 2922
 Ser Gly Gly Gly Ser Thr Val Thr Glu Asn Val Val Asn Ser
 965 970

<210> 10

<211> 974

<212> PRT

<213> Homo sapiens

<400> 10

Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
 1 5 10 15

Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
 20 25 30

Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
 35 40 45

Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
 50 55 60

Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
 65 70 75 80

Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg
 85 90 95

Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu
 100 105 110

Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe
 115 120 125

Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala
 130 135 140

Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe
 145 150 155 160

Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn
 165 170 175

Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His
 180 185 190

Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp
 195 200 205

Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu
 210 215 220

Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser
 225 230 235 240

Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val
 245 250 255

Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser
 260 265 270

Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile
 275 280 285

Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu
 290 295 300

Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe
 305 310 315 320

Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys
 325 330 335

Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp
 340 345 350

Glu Glu Thr Phe Asn Cys His Leu Arg His Leu Asn Phe Thr Asn Asn
 355 360 365

Met Gly Glu Gln Val Thr Phe Asp Glu Cys Gly Asp Leu Val Gly Asn
 370 375 380

Tyr Ser Ile Ile Asn Trp His Leu Ser Pro Glu Asp Gly Ser Ile Val
 385 390 395 400
 Phe Lys Glu Val Gly Tyr Tyr Asn Val Tyr Ala Lys Lys Gly Glu Arg
 405 410 415
 Leu Phe Ile Asn Glu Glu Lys Ile Leu Trp Ser Gly Phe Ser Arg Glu
 420 425 430
 Val Pro Phe Ser Asn Cys Ser Arg Asp Cys Leu Ala Gly Thr Arg Lys
 435 440 445
 Gly Ile Ile Glu Gly Glu Pro Thr Cys Cys Phe Glu Cys Val Glu Cys
 450 455 460
 Pro Asp Gly Glu Tyr Ser Asp Glu Thr Asp Ala Ser Ala Cys Asn Lys
 465 470 475 480
 Cys Pro Asp Asp Phe Trp Ser Asn Glu Asn His Thr Ser Cys Ile Ala
 485 490 495
 Lys Glu Ile Glu Phe Leu Ser Trp Thr Glu Pro Phe Gly Ile Ala Leu
 500 505 510
 Thr Leu Phe Ala Val Leu Gly Ile Phe Leu Thr Ala Phe Val Leu Gly
 515 520 525
 Val Phe Ile Lys Phe Arg Asn Thr Pro Ile Val Lys Ala Thr Asn Arg
 530 535 540
 Glu Leu Ser Tyr Leu Leu Leu Phe Ser Leu Leu Cys Cys Phe Ser Ser
 545 550 555 560
 Ser Leu Phe Phe Ile Gly Glu Pro Gln Asp Trp Thr Cys Arg Leu Arg
 565 570 575
 Gln Pro Ala Phe Gly Ile Ser Phe Val Leu Cys Ile Ser Cys Ile Leu
 580 585 590
 Val Lys Thr Asn Arg Val Leu Leu Val Phe Glu Ala Lys Ile Pro Thr
 595 600 605
 Ser Phe His Arg Lys Trp Trp Gly Leu Asn Leu Gln Phe Leu Leu Val
 610 615 620
 Phe Leu Cys Thr Phe Met Gln Ile Val Ile Cys Val Ile Trp Leu Tyr
 625 630 635 640

Thr	Ala	Pro	Pro	Ser	Ser	Tyr	Arg	Asn	Gln	Glu	Leu	Glu	Asp	Glu	Ile	645	650	655	
Ile	Phe	Ile	Thr	Cys	His	Glu	Gly	Ser	Leu	Met	Ala	Leu	Gly	Phe	Leu	660	665	670	
Ile	Gly	Tyr	Thr	Cys	Leu	Leu	Ala	Ala	Ile	Cys	Phe	Phe	Phe	Ala	Phe	675	680	685	
Lys	Ser	Arg	Lys	Leu	Pro	Glu	Asn	Phe	Asn	Glu	Ala	Lys	Phe	Ile	Thr	690	695	700	
Phe	Ser	Met	Leu	Ile	Phe	Phe	Ile	Val	Trp	Ile	Ser	Phe	Ile	Pro	Ala	705	710	715	720
Tyr	Ala	Ser	Thr	Tyr	Gly	Lys	Phe	Val	Ser	Ala	Val	Glu	Val	Ile	Ala	725	730	735	
Ile	Leu	Ala	Ala	Ser	Phe	Gly	Leu	Leu	Ala	Cys	Ile	Phe	Phe	Asn	Lys	740	745	750	
Ile	Tyr	Ile	Ile	Leu	Phe	Lys	Pro	Ser	Arg	Asn	Thr	Ile	Glu	Glu	Val	755	760	765	
Arg	Cys	Ser	Thr	Ala	Ala	His	Ala	Phe	Lys	Val	Ala	Ala	Arg	Ala	Thr	770	775	780	
Leu	Arg	Arg	Ser	Asn	Val	Ser	Arg	Lys	Arg	Ser	Ser	Ser	Leu	Gly	Gly	785	790	795	800
Ser	Thr	Gly	Ser	Thr	Pro	Ser	Ser	Ser	Ile	Ser	Ser	Lys	Ser	Asn	Ser	805	810	815	
Glu	Asp	Pro	Phe	Pro	Gln	Pro	Glu	Arg	Gln	Lys	Gln	Gln	Gln	Pro	Leu	820	825	830	
Ala	Leu	Thr	Gln	Gln	Glu	Gln	Gln	Gln	Gln	Pro	Leu	Thr	Leu	Pro	Gln	835	840	845	
Gln	Gln	Arg	Ser	Gln	Gln	Gln	Pro	Arg	Cys	Lys	Gln	Lys	Val	Ile	Phe	850	855	860	
Gly	Ser	Gly	Thr	Val	Thr	Phe	Ser	Leu	Ser	Phe	Asp	Glu	Pro	Gln	Lys	865	870	875	880
Asn	Ala	Met	Ala	His	Arg	Asn	Ser	Thr	His	Gln	Asn	Ser	Leu	Glu	Ala	885	890	895	

Gln Lys Ser Ser Asp Thr Leu Thr Arg His Gln Pro Leu Leu Pro Leu
 900 905 910

Gln Cys Gly Glu Thr Asp Leu Asp Leu Thr Val Gln Glu Thr Gly Leu
 915 920 925

Gln Gly Pro Val Gly Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu
 930 935 940

Glu Leu Ser Pro Ala Leu Val Val Ser Ser Ser Gln Ser Phe Val Ile
 945 950 955 960

Ser Gly Gly Gly Ser Thr Val Thr Glu Asn Val Val Asn Ser
 965 970

<210> 11

<211> 3234

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(3234)

<400> 11

atg gca ttt tat agc tgc tgc tgg gtc ctc ttg gca ctc acc tgg cac 48
 Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
 1 5 10 15

acc tct gcc tac ggg cca gac cag cga gcc caa aag aag ggg gac att 96
 Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
 20 25 30

atc ctt ggg ggg ctc ttt cct att cat ttt gga gta gca gct aaa gat 144
 Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
 35 40 45

caa gat ctc aaa tca agg ccg gag tct gtg gaa tgt atc agg tat aat 192
 Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
 50 55 60

ttc cgt ggg ttt cgc tgg tta cag gct atg ata ttt gcc ata gag gag 240
 Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
 65 70 75 80

ata aac agc agc cca gcc ctt ctt ccc aac ttg acg ctg gga tac agg 288

Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg	
85 90 95	
ata ttt gac act tgc aac acc gtt tct aag gcc ttg gaa gcc acc ctg	336
Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu	
100 105 110	
agt ttt gtt gct caa aac aaa att gat tct ttg aac ctt gat gag ttc	384
Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe	
115 120 125	
tgc aac tgc tca gag cac att ccc tct acg att gct gtg gtg gga gca	432
Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala	
130 135 140	
act ggc tca ggc gtc tcc acg gca gtg gca aat ctg ctg ggg ctc ttc	480
Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe	
145 150 155 160	
tac att ccc cag gtc agt tat gcc tcc tcc agc aga ctc ctc agc aac	528
Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn	
165 170 175	
aag aat caa ttc aag tct ttc ctc cga acc atc ccc aat gat gag cac	576
Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His	
180 185 190	
cag gcc act gcc atg gca gac atc atc gag tat ttc cgc tgg aac tgg	624
Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp	
195 200 205	
gtg ggc aca att gca gct gat gac gac tat ggg cgg ccg ggg att gag	672
Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu	
210 215 220	
aaa ttc cga gag gaa gct gag gaa agg gat atc tgc atc gac ttc agt	720
Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser	
225 230 235 240	
gaa ctc atc tcc cag tac tct gat gag gaa gag atc cag cat gtg gta	768
Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val	
245 250 255	
gag gtg att caa aat tcc acg gcc aaa gtc atc gtg gtt ttc tcc agt	816
Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser	
260 265 270	
ggc cca gat ctt gag ccc ctc atc aag gag att gtc cgg cgc aat atc	864

Gly	Pro	Asp	Leu	Glu	Pro	Leu	Ile	Lys	Glu	Ile	Val	Arg	Arg	Asn	Ile		
	275						280					285					
acg	ggc	aag	atc	tgg	ctg	gcc	agc	gag	gcc	tgg	gcc	agc	tcc	tcc	ctg	912	
Thr	Gly	Lys	Ile	Trp	Leu	Ala	Ser	Glu	Ala	Trp	Ala	Ser	Ser	Ser	Leu		
	290					295					300						
atc	gcc	atg	cct	cag	tac	ttc	cac	gtg	gtt	ggc	ggc	acc	att	gga	ttc	960	
Ile	Ala	Met	Pro	Gln	Tyr	Phe	His	Val	Val	Gly	Gly	Thr	Ile	Gly	Phe		
305					310					315					320		
gct	ctg	aag	gct	ggg	cag	atc	cca	ggc	ttc	cgg	gaa	ttc	ctg	aag	aag	1008	
Ala	Leu	Lys	Ala	Gly	Gln	Ile	Pro	Gly	Phe	Arg	Glu	Phe	Leu	Lys	Lys		
				325					330					335			
gtc	cat	ccc	agg	aag	tct	gtc	cac	aat	ggt	ttt	gcc	aag	gag	ttt	tgg	1056	
Val	His	Pro	Arg	Lys	Ser	Val	His	Asn	Gly	Phe	Ala	Lys	Glu	Phe	Trp		
			340					345					350				
gaa	gaa	aca	ttt	aac	tgc	cac	ctc	caa	gaa	ggt	gca	aaa	gga	cct	tta	1104	
Glu	Glu	Thr	Phe	Asn	Cys	His	Leu	Gln	Glu	Gly	Ala	Lys	Gly	Pro	Leu		
		355					360					365					
cct	gtg	gac	acc	ttt	ctg	aga	ggt	cac	gaa	gaa	agt	ggc	gac	agg	ttt	1152	
Pro	Val	Asp	Thr	Phe	Leu	Arg	Gly	His	Glu	Glu	Ser	Gly	Asp	Arg	Phe		
	370					375					380						
agc	aac	agc	tcg	aca	gcc	ttc	cga	ccc	ctc	tgt	aca	ggg	gat	gag	aac	1200	
Ser	Asn	Ser	Ser	Thr	Ala	Phe	Arg	Pro	Leu	Cys	Thr	Gly	Asp	Glu	Asn		
385					390					395					400		
atc	agc	agt	gtc	gag	acc	cct	tac	ata	gat	tac	acg	cat	tta	cgg	ata	1248	
Ile	Ser	Ser	Val	Glu	Thr	Pro	Tyr	Ile	Asp	Tyr	Thr	His	Leu	Arg	Ile		
				405					410					415			
tcc	tac	aat	gtg	tac	tta	gca	gtc	tac	tcc	att	gcc	cac	gcc	ttg	caa	1296	
Ser	Tyr	Asn	Val	Tyr	Leu	Ala	Val	Tyr	Ser	Ile	Ala	His	Ala	Leu	Gln		
				420				425					430				
gat	ata	tat	acc	tgc	tta	cct	ggg	aga	ggg	ctc	ttc	acc	aat	ggc	tcc	1344	
Asp	Ile	Tyr	Thr	Cys	Leu	Pro	Gly	Arg	Gly	Leu	Phe	Thr	Asn	Gly	Ser		
		435					440					445					
tgt	gca	gac	atc	aag	aaa	gtt	gag	gcg	tgg	cag	gtc	ctg	aag	cac	cta	1392	
Cys	Ala	Asp	Ile	Lys	Lys	Val	Glu	Ala	Trp	Gln	Val	Leu	Lys	His	Leu		
	450					455					460						
cgg	cat	cta	aac	ttt	aca	aac	aat	atg	ggg	gag	cag	gtg	acc	ttt	gat	1440	

Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gln Val Thr Phe Asp	
465	475 480
gag tgt ggt gac ctg gtg ggg aac tat tcc atc atc aac tgg cac ctc	1488
Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile Ile Asn Trp His Leu	
485	490 495
tcc cca gag gat ggc tcc atc gtg ttt aag gaa gtc ggg tat tac aac	1536
Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val Gly Tyr Tyr Asn	
500	505 510
gtc tat gcc aag aag gga gaa aga ctc ttc atc aac gag gag aaa atc	1584
Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn Glu Glu Lys Ile	
515	520 525
ctg tgg agt ggg ttc tcc agg gag gtg ccc ttc tcc aac tgc agc cga	1632
Leu Trp Ser Gly Phe Ser Arg Glu Val Pro Phe Ser Asn Cys Ser Arg	
530	535 540
gac tgc ctg gca ggg acc agg aaa ggg atc att gag ggg gag ccc acc	1680
Asp Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr	
545	550 555 560
tgc tgc ttt gag tgt gtg gag tgt cct gat ggg gag tat agt gat gag	1728
Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu	
565	570 575
aca gat gcc agt gcc tgt aac aag tgc cca gat gac ttc tgg tcc aat	1776
Thr Asp Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn	
580	585 590
gag aac cac acc tcc tgc att gcc aag gag atc gag ttt ctg tcg tgg	1824
Glu Asn His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe Leu Ser Trp	
595	600 605
acg gag ccc ttt ggg atc gca ctc acc ctc ttt gcc gtg ctg ggc att	1872
Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val Leu Gly Ile	
610	615 620
ttc ctg aca gcc ttt gtg ctg ggt gtg ttt atc aag ttc cgc aac aca	1920
Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe Arg Asn Thr	
625	630 635 640
ccc att gtc aag gcc acc aac cga gag ctc tcc tac ctc ctc ctc ttc	1968
Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe	
645	650 655
tcc ctg ctc tgc tgc ttc tcc agc tcc ctg ttc ttc atc ggg gag ccc	2016

Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu Pro	
660 665 670	
cag gac tgg acg tgc cgc ctg cgc cag ccg gcc ttt ggc atc agc ttc	2064
Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe	
675 680 685	
gtg ctc tgc atc tca tgc atc ctg gtg aaa acc aac cgt gtc ctc ctg	2112
Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu Leu	
690 695 700	
gtg ttt gag gcc aag atc ccc acc agc ttc cac cgc aag tgg tgg ggg	2160
Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp Gly	
705 710 715 720	
ctc aac ctg cag ttc ctg ctg gtt ttc ctc tgc acc ttc atg cag att	2208
Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gln Ile	
725 730 735	
gtc atc tgt gtg atc tgg ctc tac acc gcg ccc ccc tca agc tac cgc	2256
Val Ile Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg	
740 745 750	
aac cag gag ctg gag gat gag atc atc ttc atc acg tgc cac gag ggc	2304
Asn Gln Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys His Glu Gly	
755 760 765	
tcc ctc atg gcc ctg ggc ttc ctg atc ggc tac acc tgc ctg ctg gct	2352
Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys Leu Leu Ala	
770 775 780	
gcc atc tgc ttc ttc ttt gcc ttc aag tcc cgg aag ctg ccg gag aac	2400
Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro Glu Asn	
785 790 795 800	
ttc aat gaa gcc aag ttc atc acc ttc agc atg ctc atc ttc ttc atc	2448
Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe Ile	
805 810 815	
gtc tgg atc tcc ttc att cca gcc tat gcc agc acc tat ggc aag ttt	2496
Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe	
820 825 830	
gtc tct gcc gta gag gtg att gcc atc ctg gca gcc agc ttt ggc ttg	2544
Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu	
835 840 845	
ctg gcg tgc atc ttc ttc aac aag atc tac atc att ctc ttc aag cca	2592

Leu	Ala	Cys	Ile	Phe	Phe	Asn	Lys	Ile	Tyr	Ile	Ile	Leu	Phe	Lys	Pro		
850						855					860						
tcc	cgc	aac	acc	atc	gag	gag	gtg	cgt	tgc	agc	acc	gca	gct	cac	gct	2640	
Ser	Arg	Asn	Thr	Ile	Glu	Glu	Val	Arg	Cys	Ser	Thr	Ala	Ala	His	Ala		
865					870				875					880			
ttc	aag	gtg	gct	gcc	cgg	gcc	acg	ctg	cgc	cgc	agc	aac	gtc	tcc	cgc	2688	
Phe	Lys	Val	Ala	Ala	Arg	Ala	Thr	Leu	Arg	Arg	Ser	Asn	Val	Ser	Arg		
				885					890					895			
aag	cgg	tcc	agc	agc	ctt	gga	ggc	tcc	acg	gga	tcc	acc	cct	tcc	tcc	2736	
Lys	Arg	Ser	Ser	Ser	Leu	Gly	Gly	Ser	Thr	Gly	Ser	Thr	Pro	Ser	Ser		
				900				905						910			
tcc	atc	agc	agc	aag	agc	aac	agc	gaa	gac	cca	ttc	cca	cag	ccc	gag	2784	
Ser	Ile	Ser	Ser	Lys	Ser	Asn	Ser	Glu	Asp	Pro	Phe	Pro	Gln	Pro	Glu		
		915					920						925				
agg	cag	aag	cag	cag	cag	ccg	ctg	gcc	cta	acc	cag	caa	gag	cag	cag	2832	
Arg	Gln	Lys	Gln	Gln	Gln	Pro	Leu	Ala	Leu	Thr	Gln	Gln	Glu	Gln	Gln		
		930				935							940				
cag	cag	ccc	ctg	acc	ctc	cca	cag	cag	caa	cga	tct	cag	cag	cag	ccc	2880	
Gln	Gln	Pro	Leu	Thr	Leu	Pro	Gln	Gln	Gln	Arg	Ser	Gln	Gln	Gln	Pro		
945					950				955						960		
aga	tgc	aag	cag	aag	gtc	atc	ttt	ggc	agc	ggc	acg	gtc	acc	ttc	tca	2928	
Arg	Cys	Lys	Gln	Lys	Val	Ile	Phe	Gly	Ser	Gly	Thr	Val	Thr	Phe	Ser		
				965				970						975			
ctg	agc	ttt	gat	gag	cct	cag	aag	aac	gcc	atg	gcc	cac	agg	aat	tct	2976	
Leu	Ser	Phe	Asp	Glu	Pro	Gln	Lys	Asn	Ala	Met	Ala	His	Arg	Asn	Ser		
			980					985					990				
acg	cac	cag	aac	tcc	ctg	gag	gcc	cag	aaa	agc	agc	gat	acg	ctg	acc	3024	
Thr	His	Gln	Asn	Ser	Leu	Glu	Ala	Gln	Lys	Ser	Ser	Asp	Thr	Leu	Thr		
		995					1000					1005					
cga	cac	cag	cca	tta	ctc	ccg	ctg	cag	tgc	ggg	gaa	acg	gac	tta	gat	3072	
Arg	His	Gln	Pro	Leu	Leu	Pro	Leu	Gln	Cys	Gly	Glu	Thr	Asp	Leu	Asp		
		1010				1015					1020						
ctg	acc	gtc	cag	gaa	aca	ggc	ctg	caa	gga	cct	gtg	ggc	gga	gac	cag	3120	
Leu	Thr	Val	Gln	Glu	Thr	Gly	Leu	Gln	Gly	Pro	Val	Gly	Gly	Asp	Gln		
		1025			1030				1035					1040			
cgg	cca	gag	gtg	gag	gac	cct	gaa	gag	ttg	tcc	cca	gca	ctt	gta	gtg	3168	

Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala Leu Val Val
 1045 1050 1055

tcc agt tca cag agc ttt gtc atc agt ggt gga ggc agc act gtt aca 3216
 Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser Thr Val Thr
 1060 1065 1070

gaa aac gta gtg aat tca 3234
 Glu Asn Val Val Asn Ser
 1075

<210> 12

<211> 1078

<212> PRT

<213> Homo sapiens

<400> 12

Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
 1 5 10 15

Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
 20 25 30

Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
 35 40 45

Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
 50 55 60

Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
 65 70 75 80

Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg
 85 90 95

Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu
 100 105 110

Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe
 115 120 125

Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala
 130 135 140

Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe
 145 150 155 160

Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn
 165 170 175

Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His
 180 185 190

Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp
 195 200 205

Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro Gly Ile Glu
 210 215 220

Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser
 225 230 235 240

Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val
 245 250 255

Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser
 260 265 270

Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile
 275 280 285

Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu
 290 295 300

Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe
 305 310 315 320

Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys
 325 330 335

Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp
 340 345 350

Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu
 355 360 365

Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe
 370 375 380

Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn
 385 390 395 400

Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile
 405 410 415

Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln
420 425 430

Asp Ile Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser
435 440 445

Cys Ala Asp Ile Lys Lys Val Glu Ala Trp Gln Val Leu Lys His Leu
450 455 460

Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gln Val Thr Phe Asp
465 470 475 480

Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile Ile Asn Trp His Leu
485 490 495

Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val Gly Tyr Tyr Asn
500 505 510

Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn Glu Glu Lys Ile
515 520 525

Leu Trp Ser Gly Phe Ser Arg Glu Val Pro Phe Ser Asn Cys Ser Arg
530 535 540

Asp Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr
545 550 555 560

Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu
565 570 575

Thr Asp Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn
580 585 590

Glu Asn His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe Leu Ser Trp
595 600 605

Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val Leu Gly Ile
610 615 620

Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe Arg Asn Thr
625 630 635 640

Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe
645 650 655

Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu Pro
660 665 670

Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe
675 680 685

Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu Leu
690 695 700

Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp Gly
705 710 715 720

Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gln Ile
725 730 735

Val Ile Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg
740 745 750

Asn Gln Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys His Glu Gly
755 760 765

Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys Leu Leu Ala
770 775 780

Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro Glu Asn
785 790 795 800

Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe Ile
805 810 815

Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe
820 825 830

Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu
835 840 845

Leu Ala Cys Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu Phe Lys Pro
850 855 860

Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala Ala His Ala
865 870 875 880

Phe Lys Val Ala Ala Arg Ala Thr Leu Arg Arg Ser Asn Val Ser Arg
885 890 895

Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr Pro Ser Ser
900 905 910

Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro Gln Pro Glu
915 920 925

Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln Glu Gln Gln
 930 935 940

Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln Gln Gln Pro
 945 950 955 960

Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val Thr Phe Ser
 965 970 975

Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His Arg Asn Ser
 980 985 990

Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr
 995 1000 1005

Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu Thr Asp Leu Asp
 1010 1015 1020

Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly Gly Asp Gln
 1025 1030 1035 1040

Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala Leu Val Val
 1045 1050 1055

Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser Thr Val Thr
 1060 1065 1070

Glu Asn Val Val Asn Ser
 1075